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MUC13 Enhances Colorectal Cancer Metastasis
Abstract
Colorectal cancer (CRC) is one of the most prevalent cancer worldwide with a 5% lifetime incidence in
developed countries. It is third most common cause of cancer related death in the United States and the
second deadliest when men and women are combined. Encouragingly due to changes in dietary lifestyle,
screening colonoscopy, and advancement in treatments the mortality has decreased in recent years.
Most sporadic CRCs develop from polyploid adenomas and are preceded by intramucosal carcinomas
(stage 0), which can progress into more malignant forms. This developmental process is known as the
adenoma-carcinoma sequence. Early detection and endoscopic removal are crucial for CRC
management. The overall 5-year survival of CRC jumps noticeably from 66% to 91% if it can be diagnosed
and treated at early stages but drops down to 14% when the disease has metastasized. Metastasis is the
cause of 90% of all cancer related deaths, which necessitates the need to understand the mechanisms
regulating different progression steps. Metastasis is a complex and multistep process, whereby cancer
cells leave the primary tumor and colonize in new tissues. However, only about 0.02% of tumor cells that
detach from the primary tumor are successful in forming a metastatic lesion. After intravasation,
anchorage independent survival (Anoikis resistance) of primary tumor cell is one of the key steps in
metastasis.
The mucin MUC13 when aberrantly overexpressed in cancer has been found to lead to poor outcomes in
Pancreatic, Ovarian, Liver, and Colorectal cancer. When overexpressed in these cancers MUC13 has been
shown to increase the oncogenic activity and survival of cancer cells. The oncogenic nature of MUC13
indicates a possible role in the development of Anoikis resistance and CRC metastasis.
To understand the mechanism behind Anoikis resistance we developed and optimized an Anoikis
induction model using the low adhesion poly hema coated cell culture dishes. Two isogenic cell lines
SW480 (primary tumor site) and SW620 (metastatic tumor site) were used for this study. In our initial
experiments SW620 demonstrated less cell death compared to SW480 during Anoikis induction. High
MUC13 expression was observed in SW620 between 24-36 hours compared at 0 hours. SW620 further
showed an increase in the expression of anti-apoptotic protein Bcl2 also. Overexpression of MUC13 in
SW480 (SW480+MUC13) cells increased oncogenic phenotype such as invasion, migration, proliferation,
and colony size as compared to SW480+Vector control cells. Downregulation of MUC13 in SW620 cells
resulted in decreased oncogenic traits.
The role of MUC13 in Anoikis resistance was further investigated in the overexpression and knockdown
cell lines. When overexpressing MUC13 in SW480 cells we found increased survival compared to
SW480+Vector cells. Bcl2 expression increased while Cleaved-Caspase 3 showed decreased expression
in SW480+MUC13 compared to SW480+Vector cells. Increased MUC13 expression also increased the
metastatic potential of SW480 cells in mice. After 36 hours of Anoikis induction and then injection into
mice through the tail vein, MUC13 mice had an increased tumor burden compared to Vector mice, with
METs forming in the liver, kidneys, and lungs. This would indicate that MUC13 plays a larger part in CRC
metastasis and specific in the development of Anoikis resistance.
To understand the mechanism involving MUC13 in Anoikis resistance, we studied kinases after Anoikis
induction in the cell lines, followed by quantitative proteomics. We were able to find changes in
transcription factor YAP1 and YAP1 and β-catenin, which are known to play vital roles in cellular
development. In recent studies YAP1 and β-catenin have been shown to form a complex that promotes
tumor cell survival and increased tumorigenesis. High MUC13 expression between 24-36hrs was
observed, leading to an increase in nuclear localization of the known survival complex YAP1/β-catenin.
Further in-vitro analysis indicated that MUC13 plays a vital role through direct cooperation with YAP1 and

β-catenin, and together with increased nuclear localization of YAP1/MUC13 and β-catenin/MUC13
complexes, results in increase expression of pro-survival genes. This relationship was further examined
and validated in an in-vivo mouse model, in which high MUC13 expression led to increased YAP1 and βcatenin expression and tumorigenesis. A correlation was further observed between MUC13 and YAP1
expression in human CRC patient tissue samples with high expression in tumor tissues compared to NAT
and increased nuclear localization with elevated expression for both MUC13 and YAP1. The novel
interaction between YAP1 and MUC13 defines a new mechanism in which cells develop Anoikis
resistance in CRC.
Genetic variations in genes are a well-known aspect of most diseases. This is especially true for cancer.
Genetic variations in mucins such as MUC1 and MUC5AC have been found to increase the risk of
stomach cancer and certain Allele mutations nearly doubling that risk in. We investigated if MUC13 had
any genetic variants and found 5 different splice variants. Three of those splice variants were found to be
non-coding. We then investigated the two protein coding variants consisted of a 512aa (Long form) and
187aa (Short form). We found that MUC13-LF was responsible for generating the oncogenic phenotype
associated with adherent MUC13 expression. MUC13-SF however, showed a decrease in migration and
invasion when overexpressed in MUC13 null cell lines.
These studies suggest an oncogenic function of MUC13 in CRC via influencing multiple signaling
pathways however, its role in cancer metastasis is remains elusive. In this study, we discovered how
MUC13 facilitates metastasis after dissemination of tumor cells from the primary tumor site through
influencing interaction and nuclear translocation of YAP1 and β-catenin followed by the expression of
their downstream pro-survival and metastasis genes. After escaping from the primary tumor this MUC13
driven molecular mechanism provides a crucial survival advantage to anchorage independent circulating
tumor cells, leading to successful and extravasation and homing new distant site for cancer metastasis.
The interaction between YAP1 and MUC13 provides a new therapeutic in the prevention of metastasis
that in combination with current chemotherapy could limit the tumor to its primary site.
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ABSTRACT

Colorectal cancer (CRC) is one of the most prevalent cancer worldwide with a 5%
lifetime incidence in developed countries. It is third most common cause of cancer related
death in the United States and the second deadliest when men and women are combined.
Encouragingly due to changes in dietary lifestyle, screening colonoscopy, and
advancement in treatments the mortality has decreased in recent years. Most sporadic
CRCs develop from polyploid adenomas and are preceded by intramucosal carcinomas
(stage 0), which can progress into more malignant forms. This developmental process is
known as the adenoma-carcinoma sequence. Early detection and endoscopic removal are
crucial for CRC management. The overall 5-year survival of CRC jumps noticeably from
66% to 91% if it can be diagnosed and treated at early stages but drops down to 14%
when the disease has metastasized.
Metastasis is the cause of 90% of all cancer related deaths, which necessitates the
need to understand the mechanisms regulating different progression steps. Metastasis is a
complex and multistep process, whereby cancer cells leave the primary tumor and
colonize in new tissues. However, only about 0.02% of tumor cells that detach from the
primary tumor are successful in forming a metastatic lesion. After intravasation,
anchorage independent survival (Anoikis resistance) of primary tumor cell is one of the
key steps in metastasis.
The mucin MUC13 when aberrantly overexpressed in cancer has been found to
lead to poor outcomes in Pancreatic, Ovarian, Liver, and Colorectal cancer. When
overexpressed in these cancers MUC13 has been shown to increase the oncogenic
activity and survival of cancer cells. The oncogenic nature of MUC13 indicates a possible
role in the development of Anoikis resistance and CRC metastasis.
To understand the mechanism behind Anoikis resistance we developed and
optimized an Anoikis induction model using the low adhesion poly hema coated cell
culture dishes. Two isogenic cell lines SW480 (primary tumor site) and SW620
(metastatic tumor site) were used for this study. In our initial experiments SW620
demonstrated less cell death compared to SW480 during Anoikis induction. High
MUC13 expression was observed in SW620 between 24-36 hours compared at 0 hours.
SW620 further showed an increase in the expression of anti-apoptotic protein Bcl2 also.
Overexpression of MUC13 in SW480 (SW480+MUC13) cells increased oncogenic
phenotype such as invasion, migration, proliferation, and colony size as compared to
SW480+Vector control cells. Downregulation of MUC13 in SW620 cells resulted in
decreased oncogenic traits.
The role of MUC13 in Anoikis resistance was further investigated in the
overexpression and knockdown cell lines. When overexpressing MUC13 in SW480 cells
we found increased survival compared to SW480+Vector cells. Bcl2 expression
increased while Cleaved-Caspase 3 showed decreased expression in SW480+MUC13
compared to SW480+Vector cells. Increased MUC13 expression also increased the
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metastatic potential of SW480 cells in mice. After 36 hours of Anoikis induction and then
injection into mice through the tail vein, MUC13 mice had an increased tumor burden
compared to Vector mice, with METs forming in the liver, kidneys, and lungs. This
would indicate that MUC13 plays a larger part in CRC metastasis and specific in the
development of Anoikis resistance.
To understand the mechanism involving MUC13 in Anoikis resistance, we
studied kinases after Anoikis induction in the cell lines, followed by quantitative
proteomics. We were able to find changes in transcription factor YAP1 and YAP1 and βcatenin, which are known to play vital roles in cellular development. In recent studies
YAP1 and β-catenin have been shown to form a complex that promotes tumor cell
survival and increased tumorigenesis. High MUC13 expression between 24-36hrs was
observed, leading to an increase in nuclear localization of the known survival complex
YAP1/β-catenin. Further in-vitro analysis indicated that MUC13 plays a vital role
through direct cooperation with YAP1 and β-catenin, and together with increased nuclear
localization of YAP1/MUC13 and β-catenin/MUC13 complexes, results in increase
expression of pro-survival genes. This relationship was further examined and validated in
an in-vivo mouse model, in which high MUC13 expression led to increased YAP1 and βcatenin expression and tumorigenesis. A correlation was further observed between
MUC13 and YAP1 expression in human CRC patient tissue samples with high
expression in tumor tissues compared to NAT and increased nuclear localization with
elevated expression for both MUC13 and YAP1. The novel interaction between YAP1
and MUC13 defines a new mechanism in which cells develop Anoikis resistance in CRC.
Genetic variations in genes are a well-known aspect of most diseases. This is
especially true for cancer. Genetic variations in mucins such as MUC1 and MUC5AC
have been found to increase the risk of stomach cancer and certain Allele mutations
nearly doubling that risk in. We investigated if MUC13 had any genetic variants and
found 5 different splice variants. Three of those splice variants were found to be noncoding. We then investigated the two protein coding variants consisted of a 512aa (Long
form) and 187aa (Short form). We found that MUC13-LF was responsible for generating
the oncogenic phenotype associated with adherent MUC13 expression. MUC13-SF
however, showed a decrease in migration and invasion when overexpressed in MUC13
null cell lines.
These studies suggest an oncogenic function of MUC13 in CRC via influencing
multiple signaling pathways however, its role in cancer metastasis is remains elusive. In
this study, we discovered how MUC13 facilitates metastasis after dissemination of tumor
cells from the primary tumor site through influencing interaction and nuclear translocation of YAP1 and β-catenin followed by the expression of their downstream prosurvival and metastasis genes. After escaping from the primary tumor this MUC13 driven
molecular mechanism provides a crucial survival advantage to anchorage independent
circulating tumor cells, leading to successful and extravasation and homing new distant
site for cancer metastasis. The interaction between YAP1 and MUC13 provides a new
therapeutic in the prevention of metastasis that in combination with current chemotherapy
could limit the tumor to its primary site.
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CHAPTER 1.

INTRODUCITON

Cancer is a major health problem in the United States, and worldwide as well.
Cancer is the second leading cause of death in the United States according to the CDC
[1]. Cancer related deaths, however, have been on a continuous decline since the 1990’s.
This is due to increased public awareness, early screening, and improved treatments [1].
One area of concern in cancer research is how the cells progress from primary tumors to
metastatic niches at distant sites within the body. In this study, we will examine a natural
defense to metastasis in Colorectal cancer, Anoikis, and propose a method in which cells
develop Anoikis resistance.

Cancer: An Overview
The most basic definition of cancer is the uncontrolled growth of cells no longer
able to perform their normal function within the body. These cells have often
accumulated various genetic and phenotypic abnormalities resulting in dysfunction and
generation of the primary tumor in the body. Often these abnormalities can be broken
down into 6 hallmarks of cancer.
•
•
•
•
•
•

Sustaining proliferative signaling
Evading growth suppressors
Resisting cell death,
Enabling replicative immortality,
Inducing angiogenesis,
Activation of invasion and metastasis.

Sustaining Proliferative Signaling
Sustaining proliferative signaling, at its most basic level, is the cancer cell’s
ability to obtain chronic proliferation. Often cancer cells become the rulers of their lives
through overcoming normal cell cycle signals resulting in hemostasis. Cancer cells
accomplish this through somatic mutations that activate additional downstream pathways,
a disruption of negative-feedback mechanisms, and excessive proliferative signaling.

Evading Growth Suppressors
Cancer cells need to overcome the natural safety valves built into the cell. Tumor
suppressors are key safety values. The suppressors. RN and TP53, are two of those main
safety values. Cancer cells accomplish evasion of these safety values through different
mechanism of contact inhibition; as well as invasion and corruption of the TGF-β
pathway. This evasion leads to cells being able to avoid natural cell limits, and truly start
to become oncogenic, through unchecked growth.
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Resisting Cell Death
The ability of cancer cell to resist apoptosis is a key hallmark of cancer. Cancer
cells often shut down apoptotic machinery or use it for its own needs. The two main ways
cells resist cell death are: the upregulating survival pathways, and related factors; and
suppressing the expression of proapoptotic factors, such as Bax, Bim, and Puma within
the cell.

Enabling Replicative Immortality
Enabling replicative immortality, or immortalization of cancer cells, is most often
observed in the cell lines used to study the cancers. Immortalization is vital for the
cancer. It allows cancers to pass along its lineage within the disease. Immortalization
manifests in cancer cells by overcoming senescence, and preventing the shorting of
telomeres, thus allowing the passage of the cancer lineage.

Inducing Angiogenesis
Cancers require large amount of sustenance to grow. Most tumors, lacking a
natural supply of nutrients, develop a necrotic core. Cancers overcome the issue of lack
of sustenance through the process of angiogenesis. Angiogenesis is the growth of new
blood vessels. The development of these new blood vessel, all devoted to the cancer,
allows the cancer to acquire the large amounts of sustenance needed for growth and
development, and for removal of the cellular waste that is produced.

Activation of Invasion and Metastasis
The cell’s ability to invade and metastasize are the major processes, which cancer
treatments try to prevent. The activation of invasion and the overall metastatic cascade in
the cancer cells are indicators that the cancer may be to spread within the body. Key
markers of invasion and metastasis are the epithelial mesenchymal transition (EMT), coop of the surrounding microenvironment, and cells gaining plasticity.

Emerging Hallmarks
Within the last 20 years, cancer research has identified additional hallmarks
identified with cancers. As result of advancements in the understanding cancer, 4 new
hallmarks of cancer have been defined.
•

Avoiding immune destruction
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•
•
•

Tumor-promoting inflammation
Genome instability and mutation
Deregulating cellular energetics

Cancer is no longer defined by just the uncontrolled growth of cells, but through
additional mechanisms that lead to dysfunctional activities within cells. The need to
further understand the hallmarks cancer specifically to understand the mechanism of
invasion and metastasis and its relationship to the spread colorectal cancer [2, 3].

Colorectal Cancer
Colorectal cancer (CRC) is the third most common cause of cancer death in the
United States among men and among women. When combining total causes of cancer
death, CRC is the 2nd most common cause of cancer deaths [4, 5]. Worldwide, CRC is
most found in developed or developing countries. It has a 5% lifetime incidence and is
responsible for 10% of all new cancer cases [6]. Despite these high numbers, overall, the
incidence and mortality of CRC are decreasing. This trend is due to increased access to
screening leading to early diagnosis, specialty care, and availability of modern treatments
including VEGF inhibitors and immunotherapies [5].
Most cases (90%) of CRC are sporadic, with genetic (5-10%), inflammatory
bowel disease (1-2%), and environmental factors less common but important in the
development of the disease [5]. Factors associated with causes include older age, gender,
hormonal influences, ureterocele anastomosis, and cholecystectomy. Environmental
contributions include diet, sedentary lifestyle, obesity, smoking, alcohol, and
occupational exposures. Hereditary colorectal cancers are mostly the result of polyposissyndromes, FAP, HNPCC and others. Ulcerative colitis, and Crohn’s disease, two
inflammatory bowel diseases, have been linked to colorectal cancer [5].
The generation of mutations in CRC is a slow process. The development of
mutations in CRC is often a decade long process [6]. Dysregulation of the Wnt/β-catenin
signaling pathway occurs in 90% of all Colorectal cancers [7, 8]. There are 6 major driver
genes responsible for CRC progression: APC, KRAS, BRAF, PIK3CA, SMAD4, and
p53. APC is a major fragment of the degradation complex for β-catenin. A mutation in
APC leads an accumulation of β-catenin and its downstream genes resulting in a stemlike
renewing.
Mutations in KRAS has been found to promote tumor progression in multiple
cancers. The loss of p53 due to mutation not only results in the inhibition of apoptosis
machinery, but it also stops an important mechanism that allows cells to acquire more
mutations. Individuals with a combination of these mutations such as KRAS, p53, and
SMAD4 were at higher risk of distant metastasis [8].
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Metastasis
The simplest definition of metastasis is the spread of cancer cells from the
primary tumor to distant organs in the body. This process consists of a cascade of steps,
often thought to be linear, but in recent studies to have shown an overlapping of steps
working simultaneously in parallel paths [9]. These steps can be broken down into local
invasion; systemic circulation; and seeding and colonization of distant sites. While we
understand that metastases operate through these steps, how it occurs is still a mystery.
The process of metastasis is an extremely inefficient. Of the millions of cells shed each
day, a very few metastasize to other parts of the body. Despite the inefficiency of
metastasis, it is still responsible for more than 90% of all cancer related death. Because
metastasis is responsible for mortality in cancer patients, it is vital to develop better
understandings of this process [10, 11].
Historically, the metastatic cascade has been described as consisting of several
steps. The first step, the penetration of the basement membrane and navigation of single
cells or collective cells through the stromal microenvironment is called Invasion and
Migration. The next step is the generation of new blood vessels to deliver nutrients to the
tumor and to provide escape routes for cancer cells is called Angiogenesis and
Intravasation. This allows new routes for the cells to infiltrate the blood and thus be
circulated to different parts of the body. The detachment of cancer cells from the ECM at
the primary tumor site allow them to intravasate into the blood stream as the circulating
tumor cells (CTCs). Only a fraction of viable CTCs successfully reaches the metastatic
site to form a pre-metastatic lesion [12]. The surviving CTCs must overcome the body’s
natural defense towards anchorage independent growth inhibition. These defenses create
a significant barrier to metastasis occurring after cells detach from the extra cellular
matrix [13-15]. Cells then circulate and arrest to the endothelium and extravasate into
new parts of the body. Cells then go through Extravasation. Extravasation is the reverse
of intravasation, where cells migrate from circulation to healthy tissue and basement
membrane to colonize in different sites within the body. The next step, Colonization, is a
process in which cancer cells seed in healthy tissue after passing through healthy tissue
generating niches. The overall process is thought to be inefficient, as there are multiple
processes that must each succeed individually in order for the metastatic process to
succeed [16].
However, the process of metastasis is not as simple as following these linear
steps. Metastatic cells proceed through this process by acquiring traits that allow for
metastasis to succeed. Most tumor consists of a heterogenetic composition. Cells that are
successful in metastasis gain the traits allowing for intravasation, survival from ECM
detachment, and successful generation of metastatic niches. Within this study we seek to
understand Anoikis, the mechanism behind the process in which cells overcome the
natural process related to the detachment of cells from the extracellular matrix and
surviving the ensuing circulation through the blood stream to colonize in new parts of the
body [11].
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Anoikis
In the process of metastasis, cancer cells acquire the key traits of altered cellular
adhesion, and of resistance to extracellular death signals [11]. Adhesion to the ECM
drives cell growth, differentiation, and cell death [17]. Anoikis is the cells natural defense
to the disruption in cellular adhesion, and detachment from the extracellular matrix.
The basic definition of Anoikis is a type of apoptosis due to absence of
attachment to the ECM and cellular adhesion in inappropriate locations [14]. There are
two key pathways of response in Anoikis the Extrinsic and the Intrinsic pathways. The
Extrinsic pathway is enacted through tumor necrosis factor receptor (TNFR) super
family. This leads the activation of FADD recruitment and activation of caspase-8. The
activation of Caspase-8 leads to the effectors caspase-3,-6, and -8.
The protein Bim acts as an activator in the Intrinsic pathway. The inhibition of
PI3K/Akt-mediation phosphorylation, and degradation by ERK leads to an increase in the
amount of Bim in the cells.
BH3-only protein sensitizers consist of the pro-apoptotic proteins Bad, Bik, Bmf,
Noxa, Puma, and Hrk. Sensitizers are responsible for inactivating Bcl-2 and Bcl-XL prosurvival mediators. However, both pathways are dependent on the cleaving of Caspase-3
to lead to cell death. There are 4 physiological conditions in which cells need to be
protected from Anoikis.
•
•
•
•

Loss of adhesion form the ECM
Loss of focal contacts during cellular migration
Loss of cell-cell contact
Protection from detachment induced autophagy

Loss of adhesion form the ECM leads a key part of cells detaching from the tumor
and circulating in the blood stream. There are 4 types of main integrins shown to be
involved in cell survival in relation to attachment to the ECM: α5β1, αvβ3, α1β1, and
α6β1. These integrins help activate distinct and diverse pathways that help to keep the
cell alive. FAK, Src Kinases, ILK, PI3k/Akt, and MAPK are the key pathways activated.
They have been shown to interfere with Anoikis when activated or overexpressed.
Loss of focal contacts during cellular migration is caused by the motility of
migrated cells. The motility of migrated cells often leads to the elongation of the cells and
weakening of the cell contact to the ECM. The motility is often achieved with the help of
anti-apoptotic signaling stemmed from cytokines such as Il-2.7.15 and interferon-α.
Finally, cells need protection from detachment induced autophagy. Autophagy a
normal process that leads to achieving hemostasis through the recycling of damaged
aspects of the cells. Autophagy is often a response to stress, such as detachment from the
ECM. However, Autophagy in cancer can act as a tumor suppressor or promotes
tumorigenesis. This is especially true in cells that have detached from the ECM, in which
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cells proceed one of two ways, 1. stall the onset of apoptosis by catabolizing of the
cellular packages generated containing proteins and organelles, or 2. proceed through the
apoptosis process.
Resistance to Anoikis, a natural occurrence, is a key aspect in cells surviving
intravasation and b being circulated through the bloodstream. There are four main
methods of Anoikis resistance within cancer cells:
•
•
•
•

Integrins switch
EMT
Deregulation and adaptation of their metabolism
Constitutive activation of anti-apoptotic pathways

Integrins switch is a switch of integrins that leads to a more metastatic state. In the
literature integrin switches have been shown that increases levels of subunits α6 and β6
integrins leads to a metastatic state and the acquisition of Anoikis resistance. Cells further
overcome Anoikis through EMT. EMT is the process in which cell obtain a mesenchymal
phenotype. Through EMT key oncogenic pathways TGF-β, Wnt, and growth factor
cascades are activated. EMT further gives cancer cells phenotypic traits of migration,
invasion, chemoresistance, plasticity, and Anoikis resistance [18, 19]. The acquisition of
these phenotypes allows for the cell to overcome Anoikis.
The third method in which cells overcome Anoikis is through Deregulation and
adaptation of their metabolism. Cancer cells modulate the Warburg effect and Autophagy
to limit the metabolic activity to have time to activate pro-survival pathways within the
cell. Constitutive activation of anti-apoptotic pathways is the last method of Anoikis
avoidance. The constitutive activation of anti-apoptotic pathways leads to the activation
of Key pro-survival pathways. PI3K/Akt is one of the most common routes for cells to
avoid Anoikis. Overexpression of the PI3k/Akt leads to continuous activation of several
receptor protein tyrosine kinases, activation of Ras mutations, loss of PTEN, alteration in
the PI3k activity, and amplification of Akt genes or its overexpression. Activation of the
Src family Kinases leads to loss of cell-to-cell contacts and scattering of cells and
activation of FAK signaling. MAPK signaling is active due to the expression of TrkB.
MAPK signaling then leads to the degradation of Bim within the cell [14].
Anoikis resistance is often the result of all 4 of these methods working in
conjunction with each other The ways in which the cells manipulate these methods to
acquire Anoikis resistance is not completely understood. In this study we are examining
the development of Anoikis resistance in Colorectal cancer [14, 15, 17, 20-22].
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MUC13 and Mucins in Metastasis

What Are Mucins?
Mucins are large extracellular proteins that are often heavily glycosylated acting
as a selective molecular barrier at the epithelial surface [23]. Mucins are expressed
throughout the body, often found in some of the harshest environments. They are found
in the respiratory system in air-water interface, the acidic environment of the stomach,
the complex environment of the intestinal tract, and secretory surfaces of organs such as:
liver, pancreas, gall bladder, kidney, salivary glands, lacrimal glands, and the eye. The
purpose of Mucins is to maintain homeostasis in the body. Mucins consist of 50-80% Olinked oligosaccharides and N-linked oligosaccharides. Mucins have the tendency to
form higher-order structures through polymerization. A hallmark of all mucins is Tandem
repeat domains. Tandem repeat domains tend to be highly O-glycosylated on their Serine
and Threonine residues to provide scaffolding for the cell to build oligosaccharides
structures. The O-glycosylation in mucins often help in specific ligand-receptors
interactions, give hydroscopic properties, and allows for possible binding of small
molecules and proteins.
Mucins can be broken down into two types, membrane and secreted. Membrane
bound mucins consist of a transmembrane domain, a short cytoplasmic tail, are associate
with cytoskeletal elements, and contain a cytosolic adaptor protein. Membrane bound
mucins have been shown to participate in signal transducing, and a go through a specific
process of cleavage occurring in the SEA domain of protein. Membrane Mucins further
contain multiple sections with homology to the EGF Family.
Secreted Mucins can be characterized by the two functions they perform. Gelforming Mucins like MUC,5AC,5B, and 6 that generate a gel around the cell when
secreted. Mucins such as MUC7 consist in the non-gel forming secreted Mucins [23-26].

Mucins in Cancer
Mucins have been found to be overexpressed in the epithelial-derived cancer. A
definite role in cancer for mucins has yet to be defined. Mucins have been found to
inhibit apoptosis, promote migration, promote invasion, promote proliferation, and
induce chemoresistance. In Colorectal cancer, mucins have been found to inhibit
apoptosis (MUC1, MUC5AC), and increase tumor burden and Ki67 in the nuclei
(MUC4) [27].
High molecular weight glycoproteins such as MUC1, MUC4, and MUC16 have
been found to play an important role in cellular transformation, and signal alteration
during EMT [28]. The mucins MUC1, MUC2, MUC4, and MUC16 have been found to
form aggregates with key immune drivers providing protection allowing for easy spread
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and colonization to metastatic sties [29]. Beyond the protection of the epithelia mucins
are to be involved in signaling pathways. MUC1 has been shown to β-catenin increases
the levels of β-catenin in the nucleus [26].

MUC13
MUC13 is a membrane bound mucins found to be overexpressed in multiple
cancers, and this overexpression often portends outcome. MUC13 is found to be normally
expressed in the large and small intestine, trachea, kidney, and the gastric epithelium
[30]. It has also been found to be aberrantly overexpressed in Pancreatic, Gastric,
Ovarian, and Colorectal cancers [31-36].
Consisting of only 511 amino acids, MUC13 is one of the smallest
transmembrane mucins [37]. The structure of MUC13 consist of a signal peptide, TR
domain, EGF-like domains, SEA domain, TM domain, and a cytoplasmic tail domain
(Figure 1-1).
In Pancreatic cancer MUC13 overexpression has been found to promote motility,
invasion, proliferation, clonogenicity, and rewiring of glucose metabolism. In Colorectal
cancer MUC13 overexpression promotes cell growth, colony formation, migration, and
Invasion. MUC13 expression has been shown to activate oncogenic proteins such as
HER2, pro-survival protein AKT, and reduction in p53 expression[38-41]. This, along
with other mucins role in inhibiting apoptosis, indicates MUC13 has a possible role in the
development of Anoikis resistance and the progression of metastasis in Colorectal cancer.

Specific Aims
Metastasis is responsible for most deaths in solid tumors. With 40-50% of all
CRC patients developing metastasis at some time during their cancer lifetime
understanding its development in CRC is vital [18]. A vulnerable step in the metastatic
cascade is the detachment of the cells from the ECM and subsequent circulation through
the blood stream. The body’s natural defense to this step is called Anoikis.
In literature the mucin MUC13 has been found to be aberrantly overexpressed in
cancer. Abnormal expression of MUC13 has led to increased proliferation, migration,
invasion, colony formation, and increased survival. Due to MUC13’s role defined in
recent studies and previous work done our lab we have identified MUC13 to have a
potential role in the development of Anoikis resistance in CRC. In this proposal we aim
to investigate how MUC13 enhances CRC metastasis through Anoikis resistance.
To study MUC13 role in the Anoikis resistance in CRC, my hypothesis for this
proposal is that MUC13 is responsible for the metastasis of CRC cells by regulating
survival pathways during anchorage independent growth. The following aims have been
purposed to test this hypothesis:

8

•

Aim 1: Characterization of mucin MUC13 in CRC tumors and validate its role via
Overexpression and Knockdown studies. To study MUC13s role in enhancement
of Anoikis resistance in CRC using in-vitro and in-vivo models.

•

Aim 2: Identify and characterize MUC13 associated proteins, pathways, and its
localization during anchorage independent growth and survival.

•

Aim 3: Characterization and validation of MUC13 isoforms responsible for its
oncogenic characteristics.

Figure 1-1. Schematic diagram and surface structure of MUC13
(A). A schematic diagram highlighting the structural features of the MUC13 protein. The
α-domain highlighted as blue contains the Signal peptide, Tandem repeat domain, EGFlike domain 1, and partial of the SEA domain. β-domain starting at the cleavage site of
the SEA domain is highlighted green and consists of the EGF-like 2 and 3 domains,
transmembrane domain, and the cytoplasmic tail domain as seen from the Nterminal(top) to the C-terminal (Bottom). (B). Diagram of MUC13 surface structure, with
each domain indicated by arrows.
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CHAPTER 2. THE DEVELOPMENT AND VALIDATION OF ANOIKIS
RESISTANCE MODEL IN COLORECTAL CANCER

Introduction
The decrease in cancer deaths in Colorectal cancer is mostly due to early
screening. Early screening keeps the disease localized at its earliest stages, consequently,
preventing it from forming distant metastatic sites. Most Colorectal cancer cases are due
to sporadic development of polypoid adenoma, which often develop into more malignant
forms. With early screening most polyps are discovered before they can go through the
adenoma-carcinoma sequence and can be successfully treated by endoscopic removal [5].
The overall five-year survival rate in CRC patients jumps to 91% from 66% when the
tumor is found local. When the malignancy is allowed to progress and metastasis to
different sites, this 5-year survival drops to 14% [4].
Metastases in solid tumor are responsible for 90% of all cancer deaths. Metastasis
is a major multistep process for which a complete understanding has yet to be achieved.
The process, however, is extremely inefficient, as only a small percentage of the millions
of cells shed from the primary tumor survive to develop a metastatic niche in distant
organs [42]. A key step occurs when the cells detach from the ECM and intravasate into
the bloodstream, circulate, and eventually arrest in the micro vessels of distant organs.
The body’s natural defense against cells detachment from the ECM, is an apoptotic
process, Anoikis. Resistance to Anoikis is a key development in the progression of
metastasis.
Anoikis is the body’s natural defense against any disruption in the cellular
adhesion, such as detachment form the ECM, and the formation of inappropriate cellular
adhesion. Anoikis is not a new apoptotic process, but one that has been previously
studied, with several mechanism of resistance proposed. The constitutive activation of
pro-survival pathways is one such mechanism. Specifically, the activation of the
PI3K/Akt is one such pro-survival pathways activated. Increased Src kinase activity and
the dysregulation of expressed integrins are two other such mechanisms proposed [14, 20,
22]. Further understanding the development of Anoikis resistance is vital with the failure
of any step in the metastatic cascades results in failure of the entire process.
Understanding the mechanism of Anoikis resistance will aide in the prevention of
metastasis.
For this study, we developed an Anoikis model in lab, to study this phenomenon
in Colorectal cancer. To stimulate a loss anchorage to ECM, cells were seeded in Polyhema coated plates and incubated for 0, 24,36, and 48 hours. At each time point, cells
were collected for various experiment readouts including, Cell Cycle, RNA isolation,
protein isolation, and other applications. The Colorectal cancer cell lines SW480 and
SW620 were chosen for this model for their isogenic nature. SW480 was derived from
the patient’s primary tumor, while SW620 was derived from a metastatic site within the
same patient. The isogenic nature of SW480 and SW620 provided a control variable and
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experimental variable to compare how the stimulation of anchorage independence
affected the cells.
In this chapter we propose to investigate Specific Aim 1 to characterize MUC13
in CRC tumors, validated its role via overexpression and knockdown studies, and to
study MUC13 role in enhancement of Anoikis resistance in CRC using in-vitro and invivo models. In investigating this aim we found that SW620 cells showed higher
resistance to cell death compared to the primary tumor cell line SW480. We found the
mucin, MUC13, which has been found to be overexpressed in colorectal cancer and often
leading to unfavorable outcomes, showed higher expression in SW620 cell lines.
MUC13, showed an increasing cyclic expression with 36 hours being its peak expression
during the stimulation. When MUC13 was overexpressed or knockdown it lead to a
reversal in the phenotype previously observed in SW480 and SW620 respectfully. We
were able to show that our model is a validate method to study the development of
Anoikis resistance in Colorectal cancer and that the mucin MUC13 plays a key role in
Anoikis resistance development.

Methods and Materials

Cell Culture
The Colorectal cell lines SW480(ATCC # CCl-228) and SW620(ATCC# CCL227) were grown in complete DMEM media without Sodium pyruvate (Gibco Cat#
11965092) with 10% FBS ad 1% antibiotic/antimycotic. The Stable cell lines
SW480+Vec, SW480+MUC13, SW620+shVec, and SW620+shMUC13, once selected,
were grown in the above mentioned DMEM mixture plus 0.2µg/mL of puromycin. All
cells were grown at 37°C supplied with 5% CO2.

Anoikis Induction
10cm plates were coated with 4mL of 20mg/ml solution of poly-HEMA (Poly 2hydroxyethyl methacrylate; Sigma Cat # P3932) in 95% ethanol. Plates were dried
overnight in a tissue culture hood before use. For induction, cells were plated in the
appropriate media and coated tissue culture plates, 10cm tissue culture plates were coated
with 4mL of poly-hema mixture. Cells were seeded at a density of 5x106 per plate and
collected at 24, 36, and 48 hours of time points for different assays.

Plasmid Generation
Lentiviral Gen III packaging plasmids pMDLg/pRRE encoding gag and pol
(#12251), pRSV-Rev encoding Rev (#12253) and pMD2.G encoding vesicular stomatitis
virus G protein (VSV-G envelope) (#12259) were procured from Addgene. Mission
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ShRNA plasmids in pLKO.1 backbone against MUC13 were procured from Sigma
(TRCN0000429044;CloneID:NM_033049.2-1949s21c1 5’CCG GGC ACA GCA CAA
GCA ATG CTT ACT CG AGT AAG CAT TGC TTG TGC TGT GCT TTT TTG3' 3’).
Lentiviral MUC13 expression plasmid (1539 bp human NM_033049.4) was procured
from abmgood (LV230821) along with empty vector. Plasmids were isolated using
Promega Midi kit as per manufacturer manual (Promega Cat# A7640) followed by
further purification by Phenol Chloroform method.

Lentivirus Production and Stable Cell Line Generation
Gen III lentiviral system was used to produce packaged virus particles. Briefly,
HEK293T (ATCC CRL-11268) cells were transfected with Gen III lentivirus packaging
plasmids along with overexpression or knockdown plasmids. Supernatant containing
packaged lentiviral particles was collected at 24, 48, and 72 hours post transfection and
concentrated to 1/10 of the original volume using Lenti-XTM Concentrator (Takara Cat #
631232) and stored at -80oC in 200µL aliquots. SW480 cells were transduced (E1faMUC13) for overexpression of MUC13 and selected with 2.5µg/mL puromycin, whereas
SW620 were transduced with pLKO.1-shMUC13 and selected with 1.5µg/mL
puromycin.

Cell Migration Assay
Cells were starving in FBS- media overnight before seed at a density of 10,000
cells in FBS-media in the upper chamber of a HTS Transwell-96 well permeable with
8µm polyester membrane (Corning Cat# 3374) with FBS+ media being added to the
bottom well. After 48-hour incubation cells were fixed with 4%PFA (Thermofisher Cat#
J61899-AP) and stained with crystal violet.

MTT Assay
Cell proliferation was determined using 3-(4,5-dimehtylthiazol-2-yl)2,5diphenyltetrazolium bromide) MTT assay. Cells were seeded at a density of 5,000
cells per well in a 96 well plates. Cells were incubated for 24,48 and 72 hours. After
incubation 20µL of 5mg/mL of MTT was added per 100µL of media of well containing
cells and incubated for 2 hours. After media containing MTT was removed and 100µL of
DMSO was added and plate was shaken for 15 minutes. After 15 minutes of vigorous
shaking the absorbance was taken at 570nm on microplate reader (Cytation 3, BioTek).
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Real-Time Cell Proliferation and Migration Assay Performed Using xCELLigence
Real-Time Cell proliferation and Migration assay were performed using the
xCELLigence System. Following manufacturers recommendations for plate preparation,
5,000 cells were seeded for cell proliferation, and 7,000 for cell migration. Plates were
then placed in the xCELLigence instrument and incubated at 37°C and 5%CO2 for the
duration of the experiment. The xCELLigence system was used to analyze the result.

Colony Formation
Colony formation was performed by seeding 200 cells per well in a 12 well plate.
After a14-day incubation period, colonies were fixed in cold methanol and stained using
crystal violet. Colonies were measured using ImageJ software (NIH.gov) and plotted.

Cell Invasion Assay
Cells were starved the night before an invasion assay in FBS- media. Cells were
then seeded at a density of 20,000 cells in the upper chamber of 8.0-micron Corning
Matrigel Invasion Chamber (Corning Cat# 354480), with FBS-media in the bottom
chamber of a 24-well plate. After approximately 12 hours media in the lower chamber
was replaced with FBS containing media. Plate was then incubated for 24 hours and cells
were fixed with cold methanol and stained with crystal violet.

Cell Cycle Analysis
1x106 cells were grown on poly-HEMA coated 6 well tissue culture plates, after
24,36, and 48 hours, Anoikis induced cells were pelleted, washed in 1xPBS, and fixed in
70% ethanol overnight at -20°C. Fixed cells were stained with Telford Reagent
containing Propidium Iodide (Sigma Aldrich Cat # P-4170) at 4oC for a minimum of 6
hours. Flow cytometry analysis were performed using Bio-Rad ZE5 Analyzer. Cells
displaying hypo-diploid DNA were regarded as apoptotic (SubG0/G1). Data, from at
least 10,000 cells, was collected and analyzed using ModFit Lit version 2.0 for cell cycle
analysis.

Whole Cell Extract and Protein Estimation
Anoikis induced cells collected at different time points were harvested, washed
1xPBS and lysed in RIPA buffer (50 mmol/L Tris, pH7.5, 150 mmol/L NaCl, 1% NP-40,
0.5% Na-deoxy Cholate, 0.1% SDS) containing a cocktail of protease and phosphatase
inhibitors (ThermoScientific Cat # 78446), with a brief sonication. Supernatant was then
collected, and Bradford assay (ThermoScientific Cat # 23238) was performed to ascertain
the amount of protein in the samples.
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Immunoblotting
Whole cell extracts, after quantification with Bradford reagent were mixed with
LDS buffer containing DTT (Invitrogen), and fractionated on 4% to 12% gradient
NuPAGE gels in 1xMOPS-SDS buffer (Invitrogen cat #) at 125V. Following
electrophoresis, gels were equilibrated for 10 minutes in transfer buffer (30 mM Bicine,
25 mM bis-Tris, 1 mM EDTA, 60 µM chlorobutanol, 20% v/v methanol) and then electro
transferred to a PVDF membrane (Immobilon-P, 0.45 µm; Millipore cat #IPVH00010)
for 2 hours at 12 V. After blocking in 10% milk, blots were probed with anti-MUC13
(Novus Cat# NBP2-25466), anti-Bcl2 (Cell signaling Cat#2872), anti-Cleaved Caspase
3(Cell signaling Cat#9662), anti-Beta Actin (Sigma Cat# A5441), and antiMUC13(abcam Cat # ab235450). After washing in 1xTBST, antibody-antigen complexes
were detected using horseradish peroxidase conjugated goat anti-rabbit or mouse
(Promega Cat# W4011, W4021) secondary antibody with an ECL Chemiluminescence
(Millipore cat# WBKLS0500). Signals were developed on X ray film, iBright Cl1500
(Invitrogen cat# A44240), or Chemidoc(Bio-Rad Cat#12003154) and quantitated using
Image J software (NIH.gov).

RNA Isolation, cDNA Generation, QT-PCR
Total RNA was extracted using the Trizol (Invitrogen Cat#15596018). Integrity
and concentration of isolated RNA were checked using Nanodrop 2000. 2µg of RNA
samples were reversed transcribed using Iscript gDNA clear kit (Bio-Rad cat#1725034).
The expression levels of MUC13(F5’ CAG ACA GTG AGT CAA CCA CAA A3’/ R5’
GGA CTT GTG CTG TTT AGG GT3’), were determined by real-time PCR (Roche
Light Cycler 480) using SYBR Green master mix (Kapabiosytems cat # KM4106). βActin (F5’ GCA TGG GTC AGA AGG ATT CC3’/R5’ AGG ATG CCT CTC TTG CTC
TG3’) was used as an internal loading control. Expression levels have been normalized
to that of β-actin and calculated using the delta-delta Ct method. The RT-PCR was run in
quadruplicate. The experiment was repeated three times.

Spheroid Formation and Viability Assay
Anoikis induced cell were harvested after36 hours, pelleted and suspended in
cultured media. Cells were Co-cultured with 3T3 mouse fibroblast at a ratio of 2:1 in an
ultra-low attachment 96 well plate. After 168 hours of growth, the spheroids were stained
using LIVE/DEAD Cell Imaging kit (Invitrogen Cat# R37601) as per manufacturer’s
manual for 15-20minutes Phase contract/GFP/Texas red images were acquired using
Bioteck microscope. The fluorescence was quantitated using Image J software
(NIH.gov).
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Tail Vein Study
All animal studies were approved by the University of Tennessee Institutional
Animal Care and Use Committee (IACUC) and performed in accordance with the
standards of the Association of Assessment and Accreditation of Laboratory Care.
Anoikis induced control and experimental cell lines were pelleted, 3xPBS washed and
70μM strainer passed, 1x106 cells per 100μL of cells SW480+Vec and
SW480+MUC13), were injected into the tail vein of SCID mice. Mice were monitored
weekly, after 8 weeks, mice were sacrificed, and organs analyzed for the metastatic
nodules. Excised organs/tumors were evaluated for different markers using
immunohistochemistry.

Immunohistochemistry Staining and Analysis
The sectioned FFPE human CRC were probed with anti-MUC13 (inhouse C14
mAb) antibodies, as described earlier, using a polymer based MACH4 IHC kit (Biocare
Medical; Concord, CA) according to the manufacturer’s recommendation. Briefly, tissues
were heated, deparaffinized, and after rehydration with graded ethanol treated with
peroxidase solution. Antigen retrieval; followed by primary/secondary antibody
treatment, with intermittent washings; the tissue sections were finally developed using
3,3′-diaminobenzidine reagent (DAB) solution for 2 minutes. No primary antibody was
taken as negative control for the specificity of IHC staining. After counterstaining with
hematoxylin then mounting, slides were digitally scanned using 3D Histech (Aperio)
scanner. Results were analyzed using case viewer software (3DHistech) and confirmed
by trained pathologists at University of Tennessee Health Science Center (UTHSC)
Pathology Department.

Human Kinase Array
SW480+Vec and SW480+MUC13 cell lysates were prepared according to the
Human Phospho-Kinase Array kit (Cat# ARY003B R&D Systems) manual. Detection
antibody (Cocktail A and B) and Streptavidin-HRP 2nd antibody were used to probe the
membrane, developed with Chemi-Reagent mix and image to film, iBright Cl1500
(Invitrogen cat # A44240), Chemi Doc (Bio-Rad Cat # 12003154).

Statistical Analysis
GraphPad Prism 7 (GraphPad Software, GraphPad La Jolla, California, USA) was
used for statistical analyses of all experimental procedures. Assays comprising with two
groups with equal or unequal variance, unpaired two-tailed Student’s t-tests or t-test with
Welch’s correction was performed, respectively. In instances with 3 or more groups, twoway ANOVA statistical tests were performed, followed by Sidak’s multiple comparison
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test for pairwise analysis. In all cases, a p-value of <0.05 was considered statistically
significant.

Results

MUC13 Shows Key Role in the Progression of Metastasis in Colorectal Cancer
In investigating MUC13 expression during CRC we first stained a cohort of 20
fixed FFPE human colorectal cancer tissue slides disturbed by stage evenly with MUC13.
MUC13 showed an increase in the intensity of staining in the tumor tissue when
compared to the normal adjacent tissue (NAT) of our cohort. Further, when quantified.
MUC13 had significantly greater staining in tumor tissue compared to NAT. When the
expression is broken down from normal colon tissue to stage 4 CRC, MUC13 expression
increase by stage. Stage II and stage III show the highest expression, before returning to
similar expression levels seen in stage I tumors. Quantification of MUC13 staining at
each stage showed a similar trend as seen in the images. MUC13 peak expression at stage
II and stage III indicate a possible role for MUC13 in the progression of metastasis in
colorectal cancer (Figure 2-1).
Increased MUC13 expression has been shown to be oncogenic in colorectal
cancer and to inhibit apoptosis in not just colorectal cancer, but pancreatic cancer as well.
Increased MUC13 expression activates key survival pathways [31, 32, 39, 43, 44]. To
further understand MUC13 possible roles, as they inhibit apoptosis and oncogenic nature
in Colorectal cancer, we probed MUC13 overexpressing SW480 cells and compared
them to their vector using a Human Phospho-Kinase Array kit. We found that MUC13
expression led to increased oncogenic markers, such as increased total β-catenin.
Increased MUC13 expression also led to increased phosphorylated STAT3 Y705, STAT3
S727, Hck, HSP60, WNK1, p53 S15, and GSK-3α/β. There was also a decrease in the
phosphorylation of FAK, AKT1/2/3, p70 S6 kinase T389, and p70 S6 kinase
T421/S424.Total β-catenin expression is shown to increase by 2.75-fold. Phosphorylated
STAT3 Y705 and S727 showed a 4.5 and a 12-fold increases respectively. The
expression profile of these proteins, and their increased or decreased phosphorylation
status, indicated that MUC13 has a key role in the progression of CRC metastasis
(Figure 2-2).

MUC13 Expression Leads to an Oncogenic Phenotype in Colorectal Cancer
With MUC13 expression showing an increase of key oncogenic markers in
SW480 cells, we needed to further understand the role of MUC13 as related to

16

Figure 2-1. MUC13 expression is upregulated in colorectal cancer
(A-B) IHC analysis of MUC13 in Normal, Adenoma, NAT, and Tumor in CRC tissues.
MUC13 IHC staining in Normal, Adenoma, normal appearing tumor adjacent, and
Tumor areas (A) and their quantitative expression (B) in human CRC tissues. (C-D) IHC
analysis of MUC13 in different stages of cancer from normal colon to stage IV. MUC13
IHC staining in NAT, stage I, II, III, and IV (C) and their quantitative expression (D) in
human CRC tissues. Original Magnifications 40x; zoomed areas 200x. Data are
represented as mean ± SEM further analyzed using an Unpaired t-test with a Welch’s
correction, or a Two-way ANOVA followed by Sidak’s multiple comparison test *p <
0.05, **p < 0.01, and ***p < 0.001 denote significant differences.
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Figure 2-2. MUC13 expression leads the upregulation or downregulation of key
kinases in cancer
(A). Human kinase array analysis of SW480+Vector and SW480+MUC13 cell lines.
Each box is labeled with their respective corresponding protein and highlighted with red
(increased expression) or blue (decreased expression). (B) Quantification of protein fold
change of GSK-3α/β(S21/S9), total β-catenin, STAT3(Y705), Hck, FAK(Y397),
STAT3(S727), AKT1/2/3(T308), p70 S6 kinase(T389), HSP60, p53(S15), p70 kinase
T421/S424, and WNK1 phosphorylation.
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the oncogenic potential of Colorectal cancer. We first probed the MUC13 profile in the
most used CRC cell lines. Probing the whole cell lysates with MUC13, we found a
generation of 4 distinct bands, the predicted 55kDA band, and three others at 120kDA,
80kDA, and 30kDA. We found that T84 had the highest expression of MUC13 followed
by LoVo, HT29, SW620, DLD1, SW480 and HCT116. This trend continues at the
mRNA level using SW480 as the control. T84 showed a 279-fold change, followed again
by LoVo at a 229-fold change (Figure 2-3). This profile of MUC13 among CRC cells
allowed us to identify possible cell lines to input into our Anoikis model. Specifically,
that SW480 and SW620 two isogenic with limited genetic variable proved to be prime
candidates for our study of Anoikis due to their differential MUC13 expression.
Due to the isogenic nature along with differential MUC13 expression between
SW620 and SW480 we selected them to generate our overexpression (SW480) and
knockdown (SW620) cell lines These cell lines were transduced with virus puromycin
and selected with puromycin. We successfully generated MUC13 overexpression at the
protein and mRNA levels in SW480 cells., while western blot and QT-PCR showed a
knockdown of MUC13 at the protein and mRNA levels in SW620 cells (Figure 2-4).
This trend was further observed at the real-time level using xCELLiegence,
showing that SW480+MUC13 had a greater number of cells that migrated and rate of
migration when compared to the vector SW480+Vector. With the loss of MUC13,
SW620 cells showed a decrease in migration. SW620+shMUC13 cells showed little to no
migration when compared to SW620+shV examined at the real-time level using
xCELLigence (Figure 2-5).
SW480+MUC13 cells showed an increase in the number of cells invaded when
compared to SW480+Vec cells. When counted SW480+MUC13 showed approximately
6x more cells invaded compared to the Vector cells (Figure 2-6). MUC13 overexpression
led to larger colony size, when compared to vector cells, while loss of MUC13 expression
led to a decrease in colony size, when compared to the vector cells (Figure 2-7). In
examining the effects of MUC13 on the cellular proliferation. SW480+MUC13 cells
showed an increase in cellular proliferation at 24, 48, and 72 Hours. The opposite was
observed when MUC13 expression was lost in SW620 cells compared to the vector.
Increased MUC13 expression preceded an increase in the rate of proliferation when
compared to the vector when examining it at real-time. SW620+shMUC13 cells showed
a decrease in the rate of proliferation when observing at real-time. The increase of
MUC13 expression led to an increase in the oncogenic potential of SW480 cells, while
the loss of MUC13 in SW620 cells led to a decrease in their oncogenic potential,
indicating a possible correlation between MUC13 expression and the oncogenic potential
in Colorectal cancer (Figure2-8).
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Figure 2-3. MUC13 expression profile in CRC cell lines at the protein and mRNA
level
(A). Western blot analysis of MUC13 expression across CRC cell lines. Arrows highlight
reported MUC13 bands, red (120kDA), green (80kDa, blue (55kDa) and yellow (30kDa).
(B). mRNA analysis by qRT-PCR of MUC13 in the indicated cell lines. Data are
represented as mean ± SEM. Two-way ANOVA followed by Sidak’s multiple
comparison test *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 denote
significant differences.
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Figure 2-4. Generation of MUC13 stable overexpression and knockdown cell lines
(A-B). Western blot analysis of MUC13 expression in MUC13 overexpression cell line
SW480+MUC13 and it corresponding vector SW480+Vector(A) and mRNA analysis of
MUC13 by qRT-PCR(B). (C-D) Western blot analysis of MUC13 expression in MUC13
knockdown cell line SW620+shMUC13 and it corresponding vector
SW620+shVector(C) and mRNA analysis of MUC13 by qRT-PCR(D). Data are
represented as mean ± SEM. Unpaired t-test followed with Welch’s correction*p < 0.05,
**p < 0.01, ***p < 0.001 and ****p < 0.0001 denote significant differences.
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Figure 2-5. MUC13 expression increases cellular migration in CRC
(A). Representative images of migration assay of MUC13 overexpressing
SW480+MUC13 cells and of SW480+Vector. (B). Quantification of the number of cells
that migrated and graphical representation of xCELLigence migration assay from 20hrs
to 50hrs. (C) representative images of the migration assay of MUC13 knockdown cell
line SW620+shMUC13 and of SW620+shVector. (D). Quantification of the number of
cells that migrated and graphical representation of xCELLigence migration assay from
40-72hrs. Data are represented as mean ± SEM. Unpaired t-test followed with Welch’s
correction*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 denote significant
differences.
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Figure 2-6. Increased MUC13 expression leads to increased cellular invasion in
SW480 cells
(A). Images of Matrigel invasion assay of SW480+Vector and SW480+MUC13 cells.
(B). Quantification of number of cells between SW480+Vector and SW480+MUC13.
Data are represented as mean ± SEM. Unpaired t-test followed with Welch’s
correction*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 denote significant
differences.
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Figure 2-7. MUC13 expression regulates colony size in CRC cells SW480 and
SW620
(A). Colony formation assay of SW480+Vector, SW480+MUC13, SW620+shVector,
and SW620+shMUC13. (B) Quantification of average colony size by area in
SW480+Vector and SW480+MUC13, and SW620+shVector and SW620+shMUC13.
Data are represented as mean ± SEM. Unpaired t-test followed with Welch’s
correction*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 denote significant
differences.
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Figure 2-8. Cell proliferation rates in SW480 and SW620 dependent upon
MUC13 expression
(A). Phase contrast images of SW480+Vector and SW480+MUC13 at 24hrs, 48hrs, and
72hrs. (B) Graphically representation of xCELLigence proliferation assay of
SW480+Vector and SW480+MUC13 from 30-72hrs and relative rate of proliferation as
measured by xCELLigence. (C) Phase contrast images of SW620+Vector and
SW620+shMUC13 at 24hrs, 48hrs, and 72hrs. (D) Graphically representation of
xCELLigence proliferation assay of SW620+shVector and SW620+shMUC13 from 40072hrs and relative rate of proliferation as measured by xCELLigence. Data are
represented as mean ± SEM. Unpaired t-test followed with Welch’s correction*p < 0.05,
**p < 0.01, ***p < 0.001 and ****p < 0.0001 denote significant differences.
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MUC13 Expression Associated with Anchorage Independent Survival in Human
Colorectal Cancer Cells
To study and better understand an important step in which metastatic cells move
out of primary tumor and survive through the circulation (anchorage independent
survival), we optimized an Anoikis induction model. In this model we used two isogenic
colorectal cancer (CRC) cell lines SW480 and SW620, which were isolated from primary
tumor site and metastatic tumor site, respectively. SW620 cells showed an increase in the
overall survival when compared to SW480 cells in an anchorage independent
environment as expected. SW620 cells incubated on low adhesion plates for 36 hours,
then reseeded at equal cell numbers on normal tissues culture dishes for 6 hours, showed
an increase in cell viability and ability to form new attachments. To further investigate
the increase in cell survival, cell cycle analysis was performed. The peak representing the
subG0 population was observed to be much smaller in SW620 cells than the peak
representing SW480 cells. The increase subG0 peak in SW480 indicated an increase in
their apoptotic population compared to that of SW620 cells. Quantitation of subG0
population of both the cell lines showed SW480 cells with 80% of the total cells
apoptotic at 48 hours compared to only 20% of SW620 cells showing to be apoptotic at
48 hours. SW620 cells showed little apoptosis from 24-48 hours with a negligible
difference between 24 and 36 hours (Figure 2-9). This suggest that SW620 with a higher
basal MUC13 expression has a higher survival tendency than that of the lower MUC13
expression SW480 during anchorage independence growth.
To verify if the apoptotic populations generated in SW480 and SW620 during
anchorage independent growth were apoptotic due to Anoikis we examined the
expression of the key survival protein marker Bcl2 and end point apoptosis marker cleave
caspase 3 [13, 15, 45]. Bcl2 showed a 4-fold increase in expression among SW620 cells
at 24 to 36 hours compared to SW480 cells at 0 hours. While SW620 had 2 times the
expression of Bcl2 at 24 and 36 hours compare to SW480 at the same time points.
Cleaved Caspase expression increased from 0 hour to 48 hours in SW480 cells, with a
peak 4 times fold change at 36 hours. The cleaved caspase 3 expression among SW620
showed minimal change across the time points staying relatively level (Figure 2-10). The
increased expression of Bcl2 and decreased expression of Cleaved Caspase 3 during
anchorage independent growth indicated that SW620 was resisting Anoikis.
As shown above and in the literature. MUC13 has proven to be oncogenic in
colorectal cancer and play a role in activation of key survival pathways in pancreatic
cancer [38, 39, 43, 46]. In our preliminary analysis, MUC13 shows a differential
expression at the mRNA level and protein level between SW480 and SW620 cell lines.
SW620 shows a higher basal MUC13 expression than the primary tumor cell line
SW480. Due to MUC13’s oncogenic nature in colorectal and pancreatic cancers, and its
differential expression among SW480 and SW620, the role of MUC13 during Anchorage
independent survival was examined. Interestingly, during anchorage induction MUC13
exhibited a cyclic expression pattern among SW480 and SW620 cell lines. The peak
expression coming at 36 hours. However, SW620 showed very high expression of
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Figure 2-9. W620 cells showed increased survival in an anchorage independent
environment
(A). Phase contrast images of isogenic cell lines SW480 and SW620 post 6hrs replating
on normal cell culture dishes after an incubation for 36hrs on low adhesion (poly-HEMAcoated) culture dishes. (B). Cell cycle analysis of SW480 and SW620 at 0, 24,36, and
48hrs after anchorage independent cell survival or Anoikis stimulation. Histogram
represents the cell cycle distribution and arrows indicate location of the Sub G0
population of SW480 and SW620 cells (C). Quantification of % Sub G0 population of
SW480 and SW620 cells at different time points. Unpaired t test., n = 3. Data are
represented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 denote significant
differences among tested cells.
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Figure 2-10. Higher MUC13 expression correlates with increased survival in
Anoikis inducing environment
(A). Cell (SW480 and SW620) were subjected to anchorage independent stimulation for
different time points (0,24,36, and 48hrs) and subjected to Western blot analysis of
MUC13, and apoptosis markers Bcl2 and Cleaved-Caspase 3 (B). Quantification (A) of
SW480 and SW620 immunoblots and qRT-PCR at 0,24,36, and 48hrs after anchorage
independent stimulation. In all panels: Data are represented as mean ± SEM. Two- way
ANOVA followed by Sidak’s multiple comparison test. *p < 0.05, **p < 0.01, ***p <
0.001 and ****p < 0.0001 denote significant differences. Data representative of at least
three individual experiments.
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MUC13. SW620 showed an 8-fold increase in MUC13 expression when compared to
SW480. SW480 showed a 2-fold increase in MUC13 expression at 36 hours. A similar
pattern was observed in the mRNA levels of MUC13. After an initial drop in expression
from 0-24 hour an increase in mRNA expression was observed with SW620 cells,
showing a 50-fold increase at 36 hours and 48 hours compared to SW480 (Figure 2-10).
This suggests that MUC13 could play an important role in the development of Anchorage
independent survival.

MUC13 Overexpression Enhances Anchorage Independent Survival
To verify the significance of MUC13 in the development of Anchorage
independent survival in the human metastatic cell line SW620, lentiviral expression
plasmid (MUC13; 1539 bp human NM_033049.4), E1F, alpha driven promoter, and
puromycin, as selection marker, were used to generate SW480+MUC13 (MUC13
overexpression) stable cell line. SW480+Vec (empty vector) was used as a control for all
the overexpression studies. After a 36-hour incubation on low attachment poly-hema
plates SW480+MUC13 cells were reintroduced to normal tissue culture plates.
SW480+MUC13 reattached at a higher density than of SW480+V cultured under similar
conditions. SW480+MUC13 cells showed significantly lower cell death during Anoikis
induction. Only 30% of the population (48 hour) showing signs of apoptosis, as
compared to SW480+Vec cells where at 48-hour population showed signs of higher
apoptosis (>50%). The population of SW480+Vec encompassed greater apoptotic
populations at 24 hour, and 36 hours as well. The apoptotic population is represented by
percentage sub G0 population. SW480+MUC13 showed increases in their apoptotic
populations from 0hr to 24 hours, however from 36 hour to 48 hour the apoptotic
populations show little to no increase (Figure 2-11).
The expression of the anti-apoptotic protein Bcl2 shows significant increase in
SW480+MUC13 cells from 0-24 hour. The expression of Bcl2 does drop in
SW480+MUC13 cells from 24 hour-36 hour, catches back in 48 hours showing a
significant difference compared to SW480+Vec. SW480+MUC13 show a 2.5 times fold
increase in expression of Bcl2 at 24 hour and 48 hours compared to SW480+Vec cells.
Cleaved Caspase 3 expression shows a significant increase in SW480+Vec compared to
SW480+MUC13 cells peaking at 36 hours. Showing a 5-fold increase from 0 hour.
SW480+MUC13 shows an increase in expression of Cleave-Caspase 3 at 24 hours, 36
hour, and 48 hours. However, this increased expression remains less than SW480+Vec
peaking with a 3-fold increase in expression compared to SW480+Vec at 0hr. MUC13
expression increase at both the mRNA levels and protein levels in SW480+MUC13 cells.
SW480+MUC13 cells express roughly a 4-fold increase in protein and 12-fold increase in
mRNA expression at 36 hours with a significant difference when compared to
SW480+Vec cells (Figure 2-12).
To understand the ability of these cells, to form a 3D bodies (representation of
microMET), after anchorage independent induction we assayed them via co-culture
method using mouse fibroblast 3T3 cells. After 36 hours incubation on low adhesion
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Figure 2-11. Ectopic MUC13 expression enhances Anoikis resistance in cancer cells
(A). Phase contrast images of SW480+Vector and SW480+MUC13 cells after incubation
on low adhesion plates for 36hrs. They were then re-plated on regular culture dishes and
images taken 6hrs after. (B) Cell cycle analysis of SW480+Vector and SW480+MUC13
cells at 0, 24,36, and 48hrs after anchorage independent stimulation. Histogram
represents the cell cycle distribution and arrows indicate location of the Sub G0
population. (C) Quantification of the % Sub G0 population of SW480+Vector and
SW480+MUC13 at different time points. Data are represented as mean ± SEM. Two-way
ANOVA followed by Sidak’s multiple comparison test *p < 0.05, **p < 0.01, ***p <
0.001 and ****p < 0.0001 denote significant differences.
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Figure 2-12. Ectopic MUC13 expression reverses cell death in SW480 cells
(A). SW480+Vector and SW480+MUC13 were subjected to anchorage independent
stimulation for different time points (0,24,36, and 48hrs) and subjected to Western blot
analysis of MUC13, and apoptosis markers Bcl2 and Cleaved-Caspase 3 (B).
Quantification (A) of SW480+Vector and SW480+MUC13 immunoblots and qRT-PCR
of MUC13 at 0,24,36, and 48hrs after anchorage independent stimulation. In all panels:
Data are represented as mean ± SEM. Two- way ANOVA followed by Sidak’s multiple
comparison test. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 denote
significant differences. Data representative of at least three individual experiments.
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poly-hema plates, and co-culturing with 3T3 fibroblast cells, SW480+MUC13 generated
significantly larger spheroids as compared to SW480+Vec under same conditions and
treatments after 5 days. SW480+MUC13 generated spheroids continued to increase in
size from day 5 to day 7, while SW480+Vec remain stagnant in growth over the same
time (Figure 2-13). To find the live cells in the spheroid, after 7 days of spheroid growth,
they were stained with LIVE/DEAD Cell Imaging kit. Interestingly, SW480+MUC13
showed a significantly larger live populations (72%) compared to SW480+Vec (58%) at
the same time (Figure 2-14). Finally, we observed that ectopic MUC13 expression in
SW480 CRC cell line leads to enhanced anchorage independent survival in human
SW480 colorectal cancer cell lines (decrease in the sensitivity to Anoikis) when cells
detach from the ECM.

Knockdown of MUC13 Expression Reduces Anchorage Independent Survival
To validate if loss of MUC13 expression to leads sensitivity towards Anoikis in
human SW620 colorectal metastatic cells, we performed loss of function studies. Mission
shRNA with 5 different MUC13 specific shRNA were used to verify the specificity, and
one shRNA was selected to generate MUC13 knockdown stable cell lines using
puromycin selection, SW620+shMUC13. SW620+shVec (empty vector) was used as a
control for all the knockdown studies. After knocking down MUC13 in SW620 cells a
decrease in the density of reattached cells after 36 hours on low adhesion plates was
observed for SW620+shMUC13, as compared to that of SW620+shVec cells with the
robust reattachment, strengthening our hypothesis and model. The cell cycle analysis of
SW620+shMUC13 during Anoikis induction showed a significantly higher apoptotic
population, especially with an increase from 20% to 40% between 24 hours to 36 hours,
which is significantly larger increase when compared to SW620+shVec cells increase
during that time period. From 36 hour to 48-hour SW620+shMUC13 continued to show
an upward trend in the apoptotic population, while SW620+shVec showed a steady
increase in its apoptotic population from 0hr to 48 hours, however the peak percentage at
48 hours is 22%, significantly less than the 60% of SW620+shMUC13 (Figure 2-15).
The knockdown of MUC13 leads to a significant decrease in anti-apoptotic
protein Bcl2 and MUC13 expression during anchorage independence when compared to
SW620+shVec. Bcl2 expression cycles during anchorage independence in
SW620+shMUC13 cells, however the expression is lower as compared to that of
SW620+shVec cells. Bcl2 expression in SW620+shMUC13 drops 20% from 24 hour to
36 hours and remains significantly less than SW620+shVec at 36 hours. SW620+shVec
cells show an increase in Bcl2 expression from 0 to 36 hours. Cleaved Caspase 3
expression significantly rises in SW620+shMUC13 from 0hr to a 10-fold increase at 24
hours before dropping to a 5-fold increase in expression compared to SW620+shVec at
0hr. At 24-hour SW620+shMUC13 shows a significantly greater expression of Cleaved
Caspase 3 compared to SW620+shVec. MUC13 expression was significantly decreased
both at protein and mRNA level, during culture in low adhesion environment for
SW620+shMUC13 cells as compared to SW620+shVec control cells (Figure 2-16).
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Figure 2-13. MUC13 expression increases metastatic potential after anchorage
independent stimulation
(A-B). Representative phase contrast images of spheroids generated from SW480+Vector
and SW480+MUC13, and SW620+shVector and SW620+shMUC13 after anchorage
independent stimulation and size analysis of spheroids at days 5,6, and 7. Unpaired t test.,
n = 3. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001
denote significant differences.
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Figure 2-14. MUC13 expression leads to increased survival of metastatic niche post
anchorage independent stimulation
(A). Outline of strategy adopted for investigation of metastatic potential after anchorage
independent stimulation through spheroid formation. (B-C). Cell viability analysis of
SW480+Vector and SW480+MUC13, and SW620+shVector and SW620+shMUC13
shows representative phase contrast and fluorescence images of live (green) and dead
(red) stains and quantification of % live and dead cells in spheroids generated from cells
at day 7 after anchorage independent stimulation. Unpaired t test., n = 3. Data are
represented as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 denote significant
differences.
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Figure 2-15. Loss of MUC13 expressions decreases Anoikis resistance in SW620
(A). Phase contrast images of SW620+shVector and SW620+shMUC13 cells after
incubation on low adhesion plates for 36hrs. They were then re-plated on regular culture
dishes and images taken 6hrs after. (B) Cell cycle analysis of SW480+Vector and
SW480+MUC13 cells at 0, 24,36, and 48hrs after anchorage independent stimulation.
Histogram represents the cell cycle distribution and arrows indicate location of the Sub
G0 population. (C) Quantification of the % Sub G0 population of SW480+Vector and
SW480+MUC13 at different time points. Data are represented as mean ± SEM. Two-way
ANOVA followed by Sidak’s multiple comparison test *p < 0.05, **p < 0.01, ***p <
0.001 and ****p < 0.0001 denote significant differences.
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Figure 2-16. MUC13 knockdown diminishes cell survival in SW620 cells
(A). SW620+shVector and SW620+shMUC13 were subjected to anchorage independent
stimulation for different time points (0,24,36, and 48hrs) and subjected to Western blot
analysis of MUC13, and apoptosis markers Bcl2 and Cleaved-Caspase 3 (B).
Quantification SW620+shVector and SW620+shMUC13 immunoblots and qRT-PCR of
MUC13 at 0,24,36, and 48hrs after anchorage independent stimulation. In all panels:
Data are represented as mean ± SEM. Two- way ANOVA followed by Sidak’s multiple
comparison test. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 denote
significant differences. Data representative of at least three individual experiments.
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The loss of MUC13 also lead to a significant decrease in the spheroid size after
anchorage independent stimulation for 36 hours and co-culture with 3T3 fibroblast cells.
SW620+shMUC13 showed a decrease in spheroid size after 5 days and showed little
growth through 7 days. SW620+shVec showed significantly larger spheroids over the
same time (Figure 2-13). SW620+shMUC13 grown spheroids after 7 days comprised of
a significantly larger dead population of cells (33%) compared to that of SW620+shVec
(18%). The loss of MUC13 in SW620 indicates an increase in sensitivity to cell death due
to detachment from the ECM (Figure 2-14).

Mouse Model Shows MUC13 Expression Iis High during Metastasis
We utilized a tail vein mouse metastatic model to evaluate in-vivo functional
impact of MUC13 overexpression and relationship during anchorage independent
survival. In order to study this, we first induce Anoikis for 36hrs in SW480+MUC13
cells and their vector counterpart. We then proceed to inject these Anoikis induced cells
into the tail vein of NSG mice. The mice were monitored by being weighed once a week
for 4.5 weeks, after which they were sacrificed, and tissue collected. The mice injected
with SW480+MUC13 overexpressing cells showed a significant drop in body weight
after 4 weeks compared to SW480+Vec mice. The lungs of the mice injected with
SW480+MUC13 cells weighed less and appeared more infected than those of the mice
injected with SW480+Vec cells. These mice showed visible tumor formation on the
tissue. The kidneys of the MUC13 mice weighed significantly greater, with larger visible
tumor formation in the tissue. SW480+Vec mice showed none of these observed tumor
formations in both the kidneys and lungs of the mice (Figure 2-17). Mice injected with
MUC13 overexpression SW480 showed a greater tumor burden indicating MUC13
involvement with CRC metastasis.

Discussion
Colorectal cancer is one of the most common cancers, being the third highest
occurrence of cancers in the United States among men and women. With an overall 5year survival rate of 66% across all stages Colorectal is the second deadliest cancer when
combining both men and women[4]. However, Stage I disease is associated with a 5-year
survival rate of 91%. In contrast, Stage IV disease is associated with a dismal 5-year
survival of 14%. This decrease is in 5-year survival of patients of Stage I and Stage IV is
just not specific to Colorectal cancer with 90% of all cancer related morbidities due to
metastasis [12, 47]. The development of metastasis is a series of complex steps, and
overall is an inefficient process with less than 0.02% of cells surviving this process [42].
One such step that needs to be overcome is the ability of cells to survive intravasation and
circulate within the blood stream before arrest at distant sites. The body, however, has a
natural defense to cells once they become detached from the ECM and from creating
abnormal cellular adhesions called Anoikis. How cells develop resistance to Anoikis and
strive is a question that need investigated.
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Figure 2-17. MUC13 enhances metastatic potential in mice after anchorage
independent stimulation
(A). In vivo metastasis induced by MUC13 overexpressing (SW480-MUC13) and
respective control (SW480-Vector) cells after tail vein injection in NSD mice. (B). Organ
weight profile of the Kidney, Lung, and Liver of mice injected with control and MUC13
overexpressing cells. Data are represented as mean ± SEM. Unpaired t-test followed with
Welch’s correction*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 denote
significant differences.

38

This investigation proposes to answer the question of how cells develop resistance to
Anoikis, by validating an anchorage independent model.

Using SW480 and SW620, two isogenic Colorectal cancer cells lines derived
from the primary tumor (SW480) and the metastatic site (SW620) from the same patient
incubated in low adhesion poly-hema, we were able to show a difference in the overall
survival of the cells. SW480 cells showed a 60% cell death at 36 hours incubation while
SW480 only showed a 20% cell death under similar conditions. SW620 cells that were
incubated in the Anoikis model for 36 hours and then seeded on normal tissue culture
plates for 6 hours showed an increase in viability when compared to SW480. This
indicates a development of Anoikis resistance in SW620 cells when compared to SW480
cells. We were also able to show an increase in Cleaved-caspase 3 the end molecule of
both the extrinsic and intrinsic pathway in Anoikis in SW480 cells compared to SW620
from with SW480 having 4-time fold change in expression at 36 hours compared to
SW620. The increase expression of Cleaved Caspase 3 expression in SW480 designates
that cells are dying through Anoikis. The increase of the pro-survival protein Bcl2 in
SW620 shows a development of resistance to Anoikis. However, this process does not
show us how these cells develop Anoikis resistance. This data indicates that we were
successful in creating an Anoikis model of study in colorectal cancer, with which we can
study how cells in Colorectal cancer develop Anoikis resistance.
MUC13 has been shown in literature to increase cell growth, migration, invasion,
and colony formation in colorectal cancer [32, 39]. MUC13 specifically has been shown
to inhibit apoptosis by indirectly activating the pro-survival pathway PI3K/Akt [39]. This
indicates that MUC13 is a possible candidate in progressing the development of Anoikis
resistance in CRC. We therefore wanted to verify that MUC13 increases the metastatic
potential in Colorectal cancer cells.
First, we stained a human cohort of fixed FFPE human colorectal cancer tissue
with MUC13. We found that MUC13 showed greater expression in tumor tissue when
compared to NAT tissue. The increase intensity of MUC13 staining in tumor tissue
illustrates a possible correlation between MUC13 expression and the development of
Colorectal cancer. This does not answer fully whether MUC13 expression leads to
increase metastatic potential in Colorectal cancer. When the cohort is examined by stages
from normal tissue to stage IV, we found a progression in MUC13 expression with stage
II and stage III showing the highest intensity. This is important because stage II and stage
III is when cancers start the beginning of the metastatic cascade. The increase expression
at these stages indicates that MUC13 could play a role in the early stage of the metastatic
cascade. This is further supported when MUC13 staining falls back to similar levels at
stage IV, as were found in stage I. Cancer cells in stage IV have mostly like already
complete the process of metastasis and formed METS in distant sites within the body
Next, we generated stable MUC13 overexpressing (SW480) and knockdown
(SW620) cell lines. With these cell lines we were able to see that increase MUC13
expression changed the phenotype in SW480 cells lines and increased its oncogenic
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potential in vitro. The loss of MUC13 expression in SW620 cells indicated a loss in
oncogenic potential with a decrease in proliferation, cell invasion, and cell migration.
When overexpressing MUC13, we found that MUC13 was responsible for increasing the
expression of oncogenic factors, such as β-catenin, and activating serval different key
markers in cancer progression. This confirms MUC13 as a possible key player in the
progression of Colorectal cancer.
The gain or loss of MUC13 expression is SW480 and SW620 cells confirmed the
oncogenic potential of MUC13 previously reported in the literature. MUC13 has been
shown to inhibit apoptosis and we examined the expression of MUC13 in Anoikis
stimulated cells. In SW620 cells we saw a cyclic increase in expression of MUC13 across
the time points with 36 hours showing the peak MUC13 expression at the protein and
mRNA levels. While this kind of expression did occur in SW480 cells this pattern was at
a much smaller scale and still lead to cell death. The lack of survival in SW480 cells that
start with a much lower basal expression of MUC13 than SW620 cells illustrates the
possible importance of MUC13 in the development of metastatic disease. To see if
MUC13 modulation would affect the survival of Colorectal cells, we placed our stable
MUC13 overexpressing and knockdown cell lines in our Anoikis model. We found a
reversal of the pervious phenotypes in both SW480 with a gain in expression of MUC13
and SW620 with a loss of MUC13. The SW480 overexpression led to an increase in
anchorage independent survival. Only 20% of SW480+MUC13 died after 36 hours. It
was further demonstrated that reduced MUC13 expression in SW620 sensitized them to
cell death, with over 40% of cells dying at 36 hours. With these modified cell lines
showing a reversal in the native phenotypes it verified that the expression of MUC13 was
crucial in the development of anchorage independent survival in SW480 and SW620. The
importance of MUC13 in development of Anoikis resistance and increase in metastatic
potential of Colorectal cancer was observed in the generation of spheroids after 36 hours
of Anoikis stimulation. Spheroids were used to stimulate the potential to generated
metastatic niches after 36 hours of anchorage independent stimulation. When
overexpressing MUC13 in SW480 cells we were able to see increase spheroid size and
viability. The loss of MUC13 resulted in a decrease in spheroid size and viability. Our
next question was to examine if MUC13 expression increasing Anoikis resistance and
metastatic potential in Colorectal cancer in-vivo.
MUC13 overexpressing SW480 cells were subjected to Anoikis stimulation for 36
hours and then injected in the tail vein of the mouse. After 4.5 weeks mice were
sacrificed, and organs were examined for metastatic nodes. MUC13 overexpression
showed an increase in tumorgenicity after injection in the tail vein. SW480+MUC13
showed tumor formation in the lungs, kidneys, and liver. With Colorectal cancer the two
main organs in which metastasis is found are the liver and lungs [48]. This indicates that
SW480+MUC13 injected cells successfully arrested in lungs and metastases to the lung
and kidneys. The successful arresting by SW480+MUC13 cells after Anoikis goes to
further validate that MUC13 is an important factor in the development of Anoikis and
metastatic progression.
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While this indicates that MUC13 plays a possible role in the development of
Anoikis resistance in Colorectal cancer it does not answer the pathologic mechanism
behind these findings. With peak MUC13 expression and survival at 36 hours and a fall
off after at 48 hours MUC13 is not the only aberration needed to confer Anoikis
resistance. This was specifically seen in the less remarkable reaction demonstrated in the
metastatic cell line SW620 with the loss of MUC13 expression. While loss of MUC13
expression does lead to increase apoptosis in SW620 cells, it is not to the same level as
SW480 cells. Further investigation is needed to define the role of MUC13 role in Anoikis
resistance and metastatic progression in Colorectal cancer. The next question we need to
answer is how MUC13 is conferring Anoikis resistance.
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CHAPTER 3. MUC13 AUGMENTS ANOIKIS RESISTANCE AND METASTIC
POTENTIAL IN COLORECTAL CANCER THROUGH INTERACTION WITH
YAP1

Introduction
Metastasis in cancer is the most deadly aspect of the disease, metastasis accounts
for 90% of all cancer related death [11]. The progression of metastasis is not a new
concept among cancer researchers; however, the exact nature has not been defined.
Metastasis from one cancer to another might share a common outline of steps, but it still
differs from one type of cancer to the next. Understanding the process is especially
pertinent in Colorectal cancer, where 40-50% of CRC patients will develop cancer in
their cancer lifetime[6, 18]. In the previous chapter we developed a model to study the
mechanism in which cells overcome the natural response and can proceed down the
metastatic cascade.
We were successful in stimulating the body’s response to anchorage
independence, and as a result, were able to identify possible mechanisms in the metastatic
cascade that help cells develop Anoikis resistance. One such mechanism that we
identified was the role of MUC13; in which SW620, exhibiting higher basal MUC13 than
their isogenic counterparts SW480, should an increase resistance to cell death. When
overexpressed in SW480 cells, MUC13 was able to confer an apoptotic resistance
phenotype during anchorage independence situations. The loss of MUC13, in SW620
cells, showed a reversal of this phenotype. While we have established that MUC13 can
confers an Anoikis resistance phenotype, how this occurs is a subject for further
investigation, as while we have observed this result, we are not sure why it occurs.
MUC13 has been shown to be highly expressed in intestinal type-gastric cancers,
with Colorectal cancer showing a similar trend. In Colorectal cancer MUC13 showed
high intensity in adenocarcinomas with poorly differentiated and late-stage tumors shown
a higher likelihood of high-intensity staining [34]. The aberrant expression of MUC13
with increased cytoplasmic and nuclear expression lead to larger tumor size in colorectal
cancer [32].
MUC13 has shown to be oncogenic in nature, and when overexpressed results in
cancerous growth among normally healthy tissue. MUC13 has been shown to protect
colorectal cancer cells, to activate the NF-κB pathway, resulting in the upregulation of
BCL-XL which results in cancerous growth [46]. Further, in both pancreatic and
colorectal cancers, MUC13 has been shown to promote pFAK, pERK, pAKT in
activating the pro-survival Akt pathway [38, 39, 49]. MUC13 has been found to alter the
biophysical properties in pancreatic cells. Levels of MUC13 can be correlated with a
decrease in modules, cellular adhesion, and the activation of key survival markers, which
indicates MUC13 promotes a possible mechanism in which Anoikis resistance is
strengthened [50]. In this study, we aim to identify how MUC13 promotes survival in an
anchorage independent environment.
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In colorectal cancer, 90% of patients have a mutation in the Wnt signaling
pathway. This mutation is often a the central oncogenic driver in the development of
colorectal cancer [8]. β-catenin is a transcription factor of this pathway. The dysregulated
expression of β-catenin is a key factor in the progression of Colorectal cancer [8].
The dysregulation of Wnt signaling however, is not the only oncogenic driver in
Colorectal cancer. YAP1 a transcription factor in the Hippo signaling pathway has been
found to be upregulated in 72.6% of Colorectal cancers. This upregulation has led to
increased proliferation, survival, drug resistance, EMT activation, and Anchorage
independent growth [51, 52]. Both signaling pathways Wnt signaling and YAP1, are
responsible for the homeostasis of the cell, with various aspect of each pathway
overlapping each other in this process [53].
In a recent studies YAP1/β-catenin has been observed to develop a unique
interplay that operates outside of their normal roles in cancer. YAP1 has been found to be
vital in progression of tumorigenesis and survival in Colorectal cancer [53-55]. Studies
have shown that YAP1/β-catenin share a cross talk often needing each other for
stabilization and regulation [56-58]. The YAP1/β-catenin interaction has been shown to
increase survival rates among cancer patients and upregulates anti-apoptotic markers such
as BIRC5 and the Bcl2 family of proteins [59-64]. In the previous chapter we found that
MUC13 expression correlated to increased survival of CRC cells during anchorage
independence. In recent studies MUC13 has been shown to interact with β-catenin. The
resulting interaction leads to the promotion of cell growth and poor outcomes in Liver
cancer. In this chapter we aim to investigate this possible interaction between
MUC13/YAP1 and β-catenin. To accomplish this, we will identify and characterize
MUC13 associated proteins, pathways and its localization during anchorage independent
growth and survival.

Methods and Materials

Cell Culture
The Colorectal cell lines SW480+Vec, SW480+MUC13, SW620+shVec, and
SW620+shMUC13; and their parental cell lines SW480(ATCC #CCL-228) and
SW620(ATCC#CCl-227) and HT29(ATCC# HTB-38), were grown in complete DMEM
media without Sodium pyruvate (Gibco Cat# 11965092) with 10%FBS ad 1%
antibiotic/antimycotic. All stable cells lines were maintained with 0.2µg/mL of
puromycin. All cells were grown at 37°C supplied with 5% CO2.
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Proteomics
Control SW480 cells, and experimental SW620 cells, were grown on low
attachment plates for 36hrs at 70% confluency to induce anchorage independence
survival pathways. Samples were than submitted for Proteomic analysis to the UTHSC
Proteomics core. The 36hrs grown cells in two groups (3 samples per group were
analyzed using iTRAQ (isotope-Coded Affinity Tags) with LTQ-Orbitrap mass
spectrometer. Briefly the cells in the two groups were lysed using Cell Lysis buffer from
Pierce Mass Spec Sample Prep Kit for Cultured Cell (P/N 84840) in a total volume of
20µL, protease digested, and the resulting peptide products from each sample were
labeled with a different isobaric tag. Labeled samples were analyzed by MS.
Bioinformatics UTHSC bioinformatics core analyzed raw mass spec data using iPathway
Guide (Advaita Bioinformatics). A 1.5-fold difference was set as cut off for significant
fold change for the analysis.

Human Kinase Array
Anoikis induced control and experimental cell lysate were prepared according to
the Human Phospho-Kinase Array kit (Cat# ARY003B R&D Systems) manual.
Detection antibody (Cocktail A and B) and Streptavidin-HRP 2nd antibody was used to
probe the membrane, developed with Chemi-Reagent mix and image to film or using
iBright Cl1500 (Invitrogen cat # A44240).

Whole Cell Extract and Protein Estimation
All cells were washed 1xPBS before being lysed in RIPA buffer (50 mmol/L Tris,
pH7.5, 150 mmol/L NaCl, 1% NP-40, 0.5% Na-deoxy Cholate, 0.1% SDS) containing a
cocktail of protease and phosphatase inhibitors (ThermoScientific Cat #78446). After a
brief sonication and spin down the supernatant was then collected. A Bradford assay (Cat
#23238) was then performed to ascertain the amount of protein in the samples.

Immunoblotting
Whole cell extracts after quantification with Bradford reagent were mixed with
LDS buffer containing DTT (Invitrogen), and fractionated on 4% to 12% gradient
NuPAGE gels in 1xMOPS-SDS buffer (Invitrogen cat #) at 125V. Following
electrophoresis, gels were equilibrated for 10 min in transfer buffer (30 mM Bicine, 25
mM bis-Tris, 1 mM EDTA, 60 µM chlorobutanol, 20% v/v methanol) and then electro
transferred to a PVDF membrane (Immobilon-P, 0.45 µm; Millipore cat #IPVH00010)
for 2hrs at 12V. After blocking in 10% milk, blots were probed with anti-MUC13 (Novus
Cat# NBP2-25466), anti-MUC13 (abcam Cat# ab235450), anti-Sox2(Cell signaling
Cat#), and anti-Beta Actin (Signal Cat# A5441). After washing in 1xTBST, antibodyantigen complexes were detected using horseradish peroxidase conjugated goat anti-
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rabbit or mouse (Promega Cat# W4011, W4021) secondary antibody with an ECL
Chemiluminescence (Millipore cat# WBKLS0500). Signals were developed on X ray
film, iBright Cl1500 (Invitrogen cat# A44240), or ChemiDoc (Bio-Rad Cat# 12003154)
and quantitated using Image J software (NIH.gov).

RNA Isolation, cDNA Generation, QT-PCR
Total RNA was extracted from cells using the Trizol (Invitrogen Cat#15596018).
Integrity and concentration of isolated RNA was checked using Nanodrop 2000. 2µg of
RNA samples was reversed transcribed using Iscript gDNA clear kit (Bio-Rad
cat#1725034). The expression levels of MUC13( F5 CAG ACA GTG AGT CAA CCA
CAA A3’/R5’GGA CTT GTG CTG TTT AGG GT’3’), C-Myc(F5’TTG TAC GGG TTC
CCA TGA AT3’/R5’AAC AGC ACA GAA AGG CCA GT3’), Axin2(F5’AGC CAA
AGC GAT CTA CAA AAG G3’/R5’AAG TCA AAA ACA TCT GGT AGG CA3’), and
Cyclin D1(F5’ CCG CTG GCC ATG AAC TAC CT3’/R5’ACG AAG GTC TGC GCG
TGT T3’) were determined by real-time PCR (Roche Light Cycler 480) using Syber
Green master mix (Kapabiosytems cat # KM4106), β-Actin (F5’ GCA TGG GTC AGA
AGG ATT CC3’/R5’AGG ATG CCT CTC TTG CTC TG3’) was used as an internal
loading control. Expression levels have been normalized to that of β-actin and calculated
using the delta-delta Ct method. The RT-PCR was run in quadruplicate and the
experiment was repeated three times.

Immunoprecipitation
Cells were fist washed 3x with ice cold PBS and then lysed with a non-denaturing
lysis buffer (20mM Tris HCl ph8, 137mM NaCl, 2% NP-40, 2mM EDTA, 1-% Glycerol)
containing a cocktail of protease and phosphatase inhibitors (ThermoScientific Cat #
78446). Lysed mixture was then rotated for 30mins at 4°C, spun down and the resulting
supernatant was then collected. After quantification with Bradford reagent 200µg of
protein was incubated overnight at 4°C with the chosen IP anti-body. Protein A magnetic
beads (Bio-Rad Cat #) were then added to mixture and incubated for 2hrs at 4°C. The
resulting IP-beads mixture was washed 3x for 5mins, and 40µL of LDS buffer
(Invitrogen) containing DTT was added to the IP-beads mixture. The resulting eluted
mixture was then run as described in the above Immunoblotting methodology.

Cyrofix
Anoikis induced cells, pelleted and after washing with 1xPBS were fixed in 4%
paraformaldehyde (PBS, pH 7.4) for 15 min at room temperature. Fixation was quenched
using 100 mM glycine in PBS for 5 minutes at room temperature. Pellets were
cryoprotected in 30% sucrose (PBS, pH 7.4) for 1 hour at 4°C and subsequently
embedded in optimal cutting temperature medium, and cryo- sectioned into 10 mm thick
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sections on slides. Prior to immunocytochemistry, sections were washed free of OCT in
PBS, pH 7.4 for 30 minutes.

Immunofluorescence
Anoikis induced cryo-protected cells, sectioned on slides were taken for
immunofluorescence and PLA studies. Sections were permeabilized with 2% Triton X100 for 5 mins, block in 10% Donkey serum for 1 hr. Slides were then incubated
overnight primary antibodies (anti-b-Catenin mAb (BD Biosciences Cat# 610154). antiYAP1 mAb (Abcam Cat#52771), and anti-MUC13 (Novus Cat# NBP2-25466) in 5%
Donkey serum. After washing, samples were incubated in Cy3 anti-rabbit and Alexa 488
anti-mouse respectively at room temperature in 5% donkey serum for 1 hr. Finally, slides
were mounted with Vector Shield with DAPI (VECTASHIELD Cat#H-2000) and images
were captured at 40x oil magnification using a confocal microscope Images were
captured using a confocal microscope (Zesis 710 UTHSC core) and analyzed using Zesis
version blue.

PLA
Anoikis induced cells were cryofixed and used for in situ PLA to detect protein
interactions in the cryo-fixed cells, as per manufacturer manual (DuolinkTM). Cryofixed
control and experimental cells on the slides were stained with MUC13/b-catenin;
YAP1/b-catenin; YAP1/MUc13 and b-catenin/MUC13 antibody set. A negative control
(no primary antibody control) was also included for specificity. DuolinkTM in situ
complementary oligonucleotide probe MINUS and PLUS [5x, secondary antibody
conjugated with a PLA oligonucleotide, anti-rabbit PLUS, anti-mouse MINUS, antirabbit MINUS, anti-mouse PLUS (Sigma-Aldrich, catalog number: DUO82029, DUO
92004, 92001, 92005,92002); were used for the amplification. All the antibodies used for
PLA were verified using the PLUS and MINUS probes of the same species as the
primary antibodies. The verified antibodies were taken as pairs (Mouse and Rabbit) for
detection of protein interaction. Images were captured at 40x oil using a confocal
microscope (Zesis 710 UTHSC core) and analyzed using Zesis version blue.

Plasmid Generation and Transfection
Mission ShRNA plasmids in pLKO.1 backbone against YAP1 were procured
from addgene (Plasmid number # 42540) sequencing targeting 5’GCC ACC AAG CTA
GAT AAA GAA .3’). Plasmids were isolated using Promega Midi kit as per
manufacturer manual (Promega Cat# A7640) followed by further purification by Phenol
Chloroform method. Plasmids were transfected into SW480+MUC13 using
Lipofectamine Ltx (Invitrogen Cat # 15338030) following manufactures
recommendations.
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Cell Migration Assay
SW480-MUC13+shC and SW480-MUC13+shYAP1Cells were starved in FBSmedia overnight before seed at a density of 10,000 cells in FBS-media in the upper
chamber of a HTS Transwell-96 well permeable with 8µm polyester membrane (Corning
Cat# 3374) with FBS+ media being added to the bottom well. After 48hr incubation cells
were fixed with 4%PFA(Cat#) and stained with crystal violet.

Cell Invasion Assay
To ascertain the effect of knocking down YAP1 in SW480+MUC13 cells were
starved the night before invasion assay in FBS- media. Cells were then seeded at a
density of 20,000 cells in the upper chamber of 8.0-micron Corning Matrigel Invasion
Chamber (Corning Cat# 354480), with FBS-media in the bottom chamber of a 24-well
plate. After approximately 12hrs media in the lower chamber was replaced with FBS
containing media. Plate was then incubated for 24hrs and cells were fixed with cold
methanol and stained with crystal violet.

Immunohistochemistry Staining and Analysis
The sectioned FFPE human CRC were probed with anti-MUC13 (inhouse C14
mAb), anti-YAP1(Abcam Cat#52771), anti-b-catenin (BD Biosciences Cat# 610154)
antibodies. Using a polymer based MACH4 IHC kit (Biocare Medical; Concord, CA)
according to the manufacturer’s recommendation. Tissues were briefly heated,
deparaffinized, and after rehydration with graded ethanol treated with peroxidase
solution. Antigen retrieval followed by primary/secondary antibody treatment, with
intermittent washings, the tissue sections were finally developed using 3,3′diaminobenzidine reagent (DAB) solution for 2 min. No primary antibody was taken as
negative control for the specificity of IHC staining. After counterstaining with
hematoxylin and mounting, slides were digitally scanned using 3D Histech (Aperio)
scanner and results were analyzed using case viewer software (3DHistech) and confirmed
by trained pathologists at University of Tennessee Health Science Center (UTHSC)
Pathology Department.

Research Involving Human Tissues
Human colorectal cancer tissues (FFPE) sections were procured from the
Department of Pathology, University of Tennessee Health Science Center (UTHSC,
Memphis, TN, USA) as per UTHSC IRB guidelines. Archived FFPE tissues were used in
this study. The tissue samples were coded to de-identify any patient information.
Therefore, it is considered that “no human subjects” were involved in this study. The
study was conducted in accordance with the Declaration of Helsinki, and the “Human
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Subject Exempt protocol” was approved by the Ethics Committee of the UTHSC,
Memphis, TN, USA; project identification code 13-02690-XM, approved on 28 August
2013.

Statistical Analysis
GraphPad Prism 7 (GraphPad Software, GraphPad La Jolla, California, USA) was
used for statistical analyses of all experimental procedures. Assays comprising with two
groups with equal or unequal variance, unpaired two-tailed Student’s t-tests or t-test with
Welch’s correction was performed, respectively. In instances with 3 or more groups, twoway ANOVA statistical tests were performed followed by Sidak’s multiple comparison
test for pairwise analysis. In all cases, a p-value of <0.05 was considered statistically
significant.

Results

Associated Kinase Pathways and Protein Involved in Anchorage Independent
Survival
Anchorage independent survival is increased with the expression of mucin
MUC13 in CRC cell lines. We have verified MUC13 role by gain and loss of function
experiments using SW 480 and SW620 cell lines to observe the result of varying
expressions of MUC13 within these cell lines. To understand the signaling proteins and
associated pathways, we utilized Kinome array and quantitative mass spec to understand
how MUC13 was conferring Anchorage independent survival in CRC. To observe the
signaling proteins and associated pathways; SW480 and SW620 cells, after 36hrs
incubation on low attachment poly-hema plates, were processed using R&D human
Kinome array profiler. SW620 cells were shown to have an increased expression of
pFAK at Y397, and pAKT1/2/3 at T308, two key anti-apoptotic markers, in their relation
to Anoikis resistance and development of anchorage independent survival [45, 65].
SW620, further, showed an increase in protein expression in pro-oncogenic protein CJun. This was a 3-fold change as compared to SW480 cells (Figure 3-1). The increase
activation of FAK and AKT1/2/3 indicate the activation of pro-survival pathways.
SW620 also showed a significant increase in expression of total β-catenin and
phosphorylated GSK-3α/β(S21/S9) at 36hrs. β-catenin showed a 1.5-fold increase in
SW620 compared to SW480 at 36hrs. Phosphorylated GSK-3α/β showed a 1.5-fold
increase in its expression in experimental SW620 cells compared to control SW480.
Downstream effectors, Axin2 and c-Myc of the Wnt signaling pathway, showed an
increase in expression across the time points at the mRNA level. The expression of
Cyclin D1 during anchorage independence showed significantly less expression in
SW620 cells when compared to SW480 cells. When MUC13, was overexpressed in
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Figure 3-1. MUC13 associated proteins and kinase involved in anchorage
independent survival
(A). Human kinase array analysis with the high (SW620) and low (SW480) MUC13
expressing isogenic cell lines after 36hrs of anchorage independent stimulation. The box
indicates differential expression of kinases with increased (red) and decreased (blue)
expression. (B) Quantitation of protein fold change of total β-catenin, GSK3-α/β
(S21/S9), AKT1/2/3(T308), p53(S46), p53(S15), FAK(Y397) and c-Jun phosphorylation.
Data are represented as mean ± SEM. Unpaired t-test followed with Welch’s
correction*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 denote significant
differences.
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SW480 cells, we saw an increase in the expression of these downstream activators in Wnt
signaling comparable SW620, with Cyclin D1 showing significant increases when
compared to the vector cells SW620+shVector. With the loss of MUC13, SW620 showed
a loss of expression in the downstream effectors of c-Myc, Axin2, and Cyclin D1
(Figure 3-2). The increase in total β-catenin and increase in downstream mRNA levels of
c-Myc and Axin 2 show an activation of Wnt signaling.
To understand the differential protein profile, we performed quantitative mass
spectrometry analysis (iTRAQ) of the CRC cell lines after induction of anchorage
independence. The advantage of using iTRAQ is that all labeled peptides are initially of
equal mass and chemically identical. During MS/MS fragmentation, peptides from
different biological samples yield distinct low-mass reporter ions that can be
quantitatively compared. Proteomic analysis of anchorage independent stimulated
SW480(control) and SW620 (experimental) showed an increase in key proteins in the
apoptotic process. The analysis showed an activation of the HIPPO signaling pathway,
with the survival protein BIRC5 showing a 2-fold increase, and pro-apoptotic proteins
PUMA, and BAD showing a 1.8- and 1.6-fold decrease in expression, respectively.
Analysis further showed an increase in key proteins YAP1(1.53 increase) and SOX2
(3.93 increase) expression related to CRC metastasis and survival (Figure 3-3). These
results were replicated in our SW620 cells, show higher YAP1 expression at 24,36, and
48hrs when compared to the SW480 cells. The next question we wanted to explore was
how the YAP1 expression profile change in our Anoikis model when we modulated the
MUC13 expression. We found that when we overexpressed MUC13, YAP1 expression
was greater than the expression in vector cells. The YAP1 expression held steady at 24hr,
and 36hrs, while the expression level dropped in the vector cells. When MUC13 was
knockdown, YAP1 expression was lower at 36, and 48hr, when compared to the
SW620+shVec cells. However, at 24hrs, SW620+shV and SW620+shMUC13 had even
expression of YAP1 (Figure 3-3Bi-iii). YAP1 expression changing with the expression
of MUC13 demonstration a possible link between MUC13 and YAP1 during Anoikis.
MUC13, β-catenin and YAP1 Cooperate During Anchorage Independent Growth
Finding that MUC13 expression modulated not only β-catenin downstream genes,
but also correlated to the expressing status of YAP1, our next question was: Does the
interaction of these three proteins, YAP1, MUC13, and β-catenin increase Anoikis
resistance in Colorectal cancer.
In Colorectal cancer YAP1 was recently found to be needed for tumor survival
and progress in to β-catenin driven cancers. YAP1 promoted survival and tumorigenesis
by forming a complex with β-catenin [54, 58]. To determine this, we first wanted to
examine if MUC13 expression effected to formation and co-localization of this complex.
Using immunofluorescence, we examined to expression of YAP1 and β-catenin, and the
subsequent co-localization, within SW480+MUC13 and SW480+Vector cells after 36hrs
of anchorage independent stimulation. YAP1 expression was mostly localized to the
nucleus of the cell in both the SW480+Vector, and SW480+MUC13 cells at the 36hrs
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Figure 3-2. MUC13 expression is associated with activation of Wnt/β-catenin
signaling
(A). Quantification of protein fold change of total β-catenin, and GSK3-α/β(S21/S9) of
kinase array seen in Figure 3-1A. (B). qRT-PCR analysis to determine the influence of
MUC13 expression on β-catenin downstream target genes (C-Myc, Axin2, and Cyclin
D1) in low and high MUC13 expressing isogenic (SW480, SW620, respectively),
MUC13 over (SW480+MUC13 & SW480+Vector) and knockdown (SW620+shVector
& SW620+shMUC13) cell lines at indicated time points after anchorage independent
survival induction. Data representative of at least three individual experiments. Data are
represented as mean ± SEM. Two-way ANOVA followed by Sidak’s multiple
comparison test. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 denote
significant differences.
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Figure 3-3. MUC13 expression leads to activation of YAP1/β-catenin crosstalk
(A). Proteomic analysis in high (SW620) and low (SW480) MUC13 expression isogenic
cell lines after 36hrs of anchorage independent stimulation. Quantification of key Anoikis
genes associated with MUC13 that were iTRAQ/PMT identified key Anoikis genes that
were upregulated or downregulated during anchorage independent stimulation. (B)
Western blot analysis and quantification of YAP1 expression in (i) SW480 & SW620, (ii)
SW480+Vector & SW480+MUC13, and (iii) SW620+shVector & SW620+shMUC13.
Data representative of at least three individual experiments. Data are represented as mean
± SEM. Two-way ANOVA followed by Sidak’s multiple comparison test multiple
comparison test. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 denote
significant differences.
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time point. The intensity of YAP1, in the nucleus, however, was greater in the
SW480+MUC13 cells when compared to that of the SW480+Vector cells. SW480 had a
higher basal β-catenin expression in both the SW480+Vector and SW480+MUC13, as
evidenced by bright β-catenin expression in the cytoplasm. In SW480+MUC13 that
expression was also seen to be localized in the nucleus as well, with SW480+Vector cells
showing little to no localization in the nucleus at 36hrs (Figure 3-4). The increased
nuclear localization of YAP1 and β-catenin in MUC13 overexpressing SW480 cells show
a possible interaction between them and activation of their respective downstream targets.
The Co-IF of YAP1 and β-catenin in SW480+MUC13 cells showed a colocalization of YAP1 and β-catenin in the nucleus indicated by the yellow color
generated at 36hrs. The vector cells showed localization of YAP1 in the nucleus and βcatenin in the cytoplasm, as there was no indication of co-localization of either YAP1 or
β-catenin. Co-IF indicates that the proteins of interest may or may not be within
proximity of each other. However, it does not actually tell us if there is an interaction
between the two targets (Figure 3-5).
To find out if these YAP1 and β-catenin are interacting with each other, we
performed a PLA experiment. This assay combines antibody-oligo conjugates, enzymatic
ligation, and PCR amplification along with a fluorescent method of detection. This
method quantitively detects in situ protein-protein interaction in cells and tissues. PLA is
a most powerful and suitable tool for quantitative detection of the protein-protein
interaction, especially in experimental procedures similar to ours, where very limited
number of cells survive. In this method, the interaction between two proteins is detected
using the corresponding two primary antibodies raised in different species. Speciesspecific secondary antibodies (PLA probes), each with a unique short DNA strand
attached to it, bind to the primary antibodies. When the PLA probes are in molecularly
proximity (<40 nm), the DNA strands can interact through a subsequent addition of two
other circle-forming DNA oligonucleotides. The interaction of two functional protein
molecules is detected by a staining dot (red dot in our experiment). In MUC13
overexpressing cells, the assay reveled that was in interaction between YAP1/β-catenin
that localized in the cytoplasm and nucleus at 36hrs.
While this interaction did take place in the SW480+Vector cells at 36hrs, it was
limited and mostly localized to the cytoplasm. The loss of MUC13 in SW620 cells at
36hrs showed a loss of localization of the interaction in the nucleus. The interaction
occurred in similar manner to the SW620+shVec cells, however, it was only localized in
the cytoplasm (Figure 3-6). In MUC13 overexpression cells, we saw a localization in the
nucleus of the complex of at 36hrs. With the localization of the YAP1/β-catenin complex
dependent on the expression of MUC13 suggests MUC13 is important for the localization
and following activation of the complex.
Our aim in this study is to further understand how MUC13 is involved in this
process. MUC13 in liver cancer has been shown to interact with β-catenin, the resulting
in the promotion of the cancer’s progression [66]. We speculated that MUC13 becomes a
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Figure 3-4. MUC13 overexpression leads to nuclear localization of YAP1 and βcatenin in SW480 after anchorage independent stimulation
(A-B). Immunofluorescences of YAP1 and β-catenin after 36hrs of anchorage
independent stimulation. (A) YAP1 immunofluorescence in SW480+Vector and
SW480+MUC13 indicated by the red color. (B) β-catenin immunofluorescence in
SW480+Vector and SW480+MUC13 indicated by the green color. Each panel is broken
down by target staining, DAPI staining, and merged of target and DAPI. Arrows indicate
localization of fluorescence Images are representative of at least three individual
experiments. Scale bars, 50 mm.
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Figure 3-5. MUC13 expression leads to a co-localization of YAP1/β-catenin in
Anoikis resistance
Co-Immunofluorescences of YAP1 and β-catenin after 36hrs of anchorage independent
stimulation. Image is broken down into a panel of each target, DAPI, and merged image
of all panels. Arrows indicated where co-localization is occurring within the cell. Images
are representative of at least three individual experiments. Scale bars, 50 mm.
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Figure 3-6. MUC13 expression is needed for YAP1 and β-catenin to interact
within the nucleus
(A). Proximity ligation assay of YAP1 and β-catenin in MUC13 overexpressing and
vector control SW480 stable cell lines after 36hrs anchorage independent stimulation. (B)
PLA of YAP1 and β-catenin in MUC13 knockdown and vector control SW620 stable cell
lines after 36hrs anchorage independent stimulation. Each panel consist of image of
YAP1/β-catenin interaction, DAPI, and merged of the first two panels. Red dots indicate
by yellow arrows display interaction of two target proteins and localization within the
cell. Scale bars, 50 µm.
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third point in the YAP1/β-catenin complex as it interacts with YAP1. First, we performed
an immunoprecipitation of YAP1 with MUC13 in non-Anoikis induce SW620 cells.
MUC13 was able to pull out MUC13 in the cells faintly, as shown by bands at 120 and
30kDA. When examining for YAP1, there is an extremely weak band for YAP1.
However, YAP1 was able to pull out MUC13 and YAP1, as revealed by the bands of
protein at 120, and 30kDA in the MUC13 blot. To confirm if this trend was not confined
to one cell line, we preformed IP with YAP1 in the colorectal cell line HT29, which have
both a high MUC13 and YAP1 expression. We were able to see, in HT29, after pulldown
with YAP1, that MUC13 was immunoprecipitated with YAP1 as shown by the bands at
120 and 30kDA, highlighted by the yellow arrows. While we have established an
interaction between YAP1 and MUC13, whether this interaction is vital to cells
overcoming Anoikis has not been identified (Figure 3-7).
Next, we performed an PLA assay, in which we examine MUC13/YAP1 and
MUC13/β-catenin. We found that at 36hrs both YAP1 and β-catenin interacted with
MUC13. In SW480+MUC13 cells YAP1/MUC13 had a greater number or interactions
than SW480+Vector cells. This interaction mostly localized in the nucleus, with limited
evidence reveling the same localization in SW480+MUC13 cells. MUC13/β-catenin
interaction in at 36hrs of anchorage independent stimulation, showed a similar trend to
that of YAP1/MUC13. With SW480 cells having a high basal expression of β-catenin the
vector cells had a similar number of interactions as the SW480+MUC13 cells but lack the
localization to the nucleus of the SW480+MUC13 cells (Figure 3-8). MUC13 showing to
interact with YAP1 and β-catenin in the nucleus indicates the formation of a
MUC13/YAP1/β-catenin complex during Anoikis.

YAP1 and MUC13 Expression Is Needed for Tumor Progression in Colorectal
Cancer
The novel cooperation between YAP1 and MUC13, that we identified, indicates a
possible mechanism in which MUC13 confers Anoikis resistance to Colorectal cancer
cells. In literature it is has been shown that an interaction between MUC13 and β-catenin
can lead to poor prognosis, and lead to metastasis in Colorectal cancer and Liver cancer
[41, 66]. PLA has shown us that MUC13 interacts with both YAP1, and β-catenin, and in
the previous chapter we showed the need of MUC13 expression in conferring Anoikis
resistance.
We do not know however, if YAP1 expression is needed for this mechanism to
work. To explore the role of YAP1 expression, we proceeded to knockdown YAP1
expression in MUC13 overexpression cells SW480+MUC13 and examine the change in
phenotype. We then confirmed the knockdown of YAP1 via western blot and QT-PCR,
in which we saw a decrease in expression at the protein and mRNA levels of YAP1.
MUC13 expression was then probed at the protein and mRNA levels. In cells in which
we successfully knockdown YAP1, we saw an increase in the mRNA levels of MUC13
and the intensity of MUC13 at 55, and 30kDA bands. In our lab group we have found
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Figure 3-7. MUC13 physical interacts with YAP1
(A). Western blot analysis of immunoprecipitation of MUC13 and YAP1 by MUC13 in
SW620 cells. (B) Western blot analysis of immunoprecipitation of MUC13 and YAP1 by
YAP1 in SW620 cells. (C) Immunoprecipitation of MUC13 by YAP1 in HT29 followed
by western blot analysis. Target bands are indicated by yellow arrows and read from left
to right as In(input), BT (breakthrough), and IP(Immunoprecipitation).
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Figure 3-8. MUC13 interacts and form molecular complex with β- catenin and
YAP1 to facilitate anchorage independent survival of cancer cells
(A). PLA of MUC13 and YAP1 in SW480+MUC13 and SW480+Vector after 36hrs
anchorage independent stimulation. (B). PLA of MUC13 and β-catenin in MUC13
overexpressing and vector control SW480 stable cell lines after 36hrs anchorage
independent stimulation. Panels consist of interaction (YAP1/MUC13 or MUC13/βcatenin), DAPI and merged image. Yellow arrows highlight interaction indicated by red
dots.
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that the band at 120kDA is the most associated band with oncogenicity of MUC13. With
the loss of YAP1 expression we see a decrease in the intensity of that band (Figure 3-9).
Using the phenotypic assay cell migration and cell Invasion, we found that when YAP1
expression is knockdown in SW480+MUC13, there was a reduction in the number of
cells that invaded and migrated (Figure 3-10). The loss of YAP1 and subsequent loss of
oncogenicity in MUC13 indicates YAP1 expression is need for the oncogenic activity of
MUC13.
Mouse Model Shows MUC13, β-catenin and YAP1 Expression Are High during
Metastasis
To examine this interaction of MUC13/YAP1/β-catenin in-vivo SW480+Vector
and SW480+MUC13 after 36hrs of Anoikis stimulation, these cells were injected into the
tail vein of mice. After termination of the mice, lung and kidney tissues were collected
and stained with MUC13, YAP1, and β-catenin. Among the kidney tissue, there was a
significant difference among the intensity of MUC13, YAP1, and β-catenin in
SW480+MUC13 mice. The kidney and lung tissue of mice injected with
SW480+MUC13 cells showed a significant difference in the number of MacroMETs
(>400µm), and microMETs(<400µm) compared to SW480+Vector. In kidney MUC13
mice showed an average formation of 3 microMETs, and 20 microMETs, compared to an
average of 0 microMETs, and macroMETs in the Vector mice. Similarly, MUC13 mice
showed a greater number of average microMETs (17) and macroMETs (21) compared to
number of microMETs (4) and macroMETs (2) in Vector mice. In the primary tumor
formation site of the mice, the lungs; YAP1, β-catenin, and MUC13, produced no
observable difference in staining intensity. In the secondary tumor site, the kidneys, there
was a distinctly observable difference in staining intensity of MUC13, YAP1, and βcatenin (Figure 3-11).
β-catenin and YAP1 staining in the kidneys showed localized staining on the
membrane and cytoplasm in vector mice. In MUC13 mice, the β-catenin, YAP1 and
MUC13 staining showed localization in the membrane, cytoplasm, and nucleus. The
kidneys of Vector mice showed no MUC13 staining. In the Lungs, YAP1 and β-catenin
staining was localized to the cytoplasm and nucleus in both the Vector and MUC13 mice.
MUC13 staining was found to be localized at the membrane and cytoplasm in both the
Vector and MUC13 mice. Nuclearization of MUC13, YAP1, and β-catenin showed an
increased in tumor formation indicating a collaborative role in the progression of CRC
metastasis.

MUC13 and YAP1 Expression Positively Correlate in Human CRC Tissues
To verify MUC13 and YAP1 correlation in human samples, we utilized well annotated
human CRC tissues. In previous studies, a correlation showing that increased MUC13
expression led to activation and nuclearization of β-catenin, which in turn lead to
decreased OS and DFS in liver cancer [41, 66]. With a clinical link established between
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Figure 3-9.
Knockdown of YAP1 alters MUC13 expression in SW480+MUC13
cells
(A). Western blot analysis of MUC13 and YAP1 in SW480_MUC13+shYAP1, and
SW480_Vector+shControl. Yellow arrows highlight bands of interest in both YAP1 and
MUC13. (B) mRNA analysis of YAP1 and MUC13 in SW480_MUC13+shYAP1, and
SW480_Vector+shControl cells. Data are represented as mean ± SEM. Unpaired t-test
followed with Welch’s correction*p < 0.05, **p < 0.01, ***p < 0.001 and ****p <
0.0001 denote significant differences.
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Figure 3-10. Knockdown of YAP1 leads to decrease in oncogenicity of
SW480+MUC13 cells
(A). Representative images of Matrigel invasion assay of SW480_MUC13+shYAP1 and
SW480_MUC13+shControl and quantification of the number of cells invaded. (B)
Images of cellular invasion and quantification of the number of cells invaded of
SW480_MUC13+shYAP1 and SW480_MUC13+shControl. Data are represented as
mean ± SEM. Unpaired t-test followed with Welch’s correction*p < 0.05, **p < 0.01,
***p < 0.001 and ****p < 0.0001 denote significant differences.

62

Figure 3-11. Increased MUC13 staining increases YAP1 and β-catenin in
metastatic lesion in mice
(A). IHC analysis in lungs and kidney to demonstrate MUC13, YAP1 and β-catenin
protein expression in metastatic lesions. (B) Quantification and profile of MacroMETS
and MicroMETS in the lungs and kidneys in MUC13 overexpressing and Vector mice.
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MUC13 and β-catenin, we looked at the relationship between YAP1 and MUC13 in
colorectal cancer, to see if a similar link can be established. Among 19 CRC human
tissue samples we found a significant increase in the expression of MUC13 in the tumor
compares to normal tissue as seen in Chapter 2. When examining YAP1 expression
among those same 19 tissues we also found a significant increase in expression between
normal tissue and tumor tissue. YAP1 showed its greatest intensity at stages II and VI
(Figure 3-12). Out of tissues studied, four were found to have nuclear staining of
MUC13. These four samples showed an average staining of 197 for YAP1, and 236 for
MUC13. The expression of MUC13 in non-nuclear MUC13 staining was 211 and the
expression of YAP1 the average score was 162 (Figure 3-13). The increased intensity of
both YAP1 and MUC13 when MUC13 was found in the nucleus suggests their nuclear
collaboration role in the progression of CRC.

Discussion
Metastasis is the single most deadly aspect of cancer, as it is responsible for 90%
of all cancer related morbidities in solid tumors [11]. The complex process of metastasis
consists of multiple steps. A failure in anyone of those steps results in the failure of the
entire process [42]. One of these steps involves a process that provides the ability of cells
to overcome the natural apoptotic process of Anoikis.
Anoikis is the cell’s response to it becoming detached from the ECM, and the
ability of cells in forming adherent cellular contacts downstream. Using an anchorage
independent growth model, to stimulate this response amongst cancer cells, we have
shown that MUC13 influences this process in Colorectal cancer.
Using Proteomics and Human Kinase arrays, we probed for key proteins that were
involved in the process. Proteomics of the SW480 and SW620 cells after 36hrs in
anchorage independent growth showed a decrease in the pro-apoptotic genes PUMA and
BAD in SW620. The downregulation indicates that most likely SW620 cells have
activated pro-survival pathways, such as the Akt signaling pathway. This result was
further supported in the probing, using the Human Kinase array, as indicated by increase
phosphorylation of Akt and FAK. Proteomics further indicated the activation Hippo
signaling pathway, with upregulation of YAP1and the downstream factor, BIRC5.
Increased expression of BRIC5, has been found in a recent study, to be a resulting factor
in the formation of a YAP1/β-catenin complex that drives tumor survival and
tumorigenesis of Colorectal cancer [54].
The Human Kinase further supports the notation of this complex forming showing
an increase of total β-catenin and increase phosphorylation of GSK-3α/β inactivating the
degradation complex. This complex was found to regulate pro-survival pathways, as well
as activating other downstream effectors, such as Wnt/β-catenin signaling.
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Figure 3-12. YAP1 expression positively correlates in human CRC tissues
(A). IHC analysis of YAP1 staining in NAT versus Tumor areas and quantification of
expression in human CRC tissues. (B). IHC analysis of YAP1 in different stages of
human CRC tissues and quantification of scores broken down by different stages.
Unpaired t test followed with Welch’s correction and Two-way ANOVA followed by
Sidak’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p <
0.0001 denote significant differences.
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Figure 3-13. YAP1 and MUC13 nuclear localization positively correlates in human
CRC tissues
(A). MUC13 and YAP1 showing nuclear staining in human CRC tissues of same
patients. Yellow arrows indicate nuclear staining of MUC13 and YAP1 in the zoomed
areas. (B) Quantification of MUC13 and YAP1 in human CRC tissues when MUC13 is
found in the nucleus versus when it remains non-nuclear
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To determine MUC13’s expression on the effect of two key aspect of this
complex YAP1 and β-catenin, we first checked the mRNA levels of downstream βcatenin genes c-Myc, Axin2, and Cyclin D1 in SW480, SW620 and MUC13
overexpression, and knockdown MUC13 cell lines. In SW620 cells c-Myc and Axin 2
showed an increase expression across all time points when compared to SW480 cell lines.
SW480 showed a higher Cyclin D1 expression than SW620. However, this difference is
most likely related to the difference between the two cell lines and is not influence by
MUC 13.
When MUC13 is overexpressed in SW480 cells, there is a higher Cyclin D1
expression across the time points as well as Axin2. C-Myc showed higher expression at
0hr and 36hr while showing similar levels at 24 and 48hrs. Loss of MUC13 showed a
decrease of these genes across anchorage independent stimulation, indicating that
MUC13 is influence the activity of β-catenin in Anoikis stimulate cells.
Next, we examined YAP1 expression, and found that in SW620, and in MUC13
overexpression, cells that YAP1 expression increase across Anoikis. The loss of MUC13
resulted in a loss of YAP1 expression during Anoikis. This together with the stimulation
β-catenin genes indicate that MUC13 is influencing the formation of the survival
complex of YAP1/β-catenin.
Co-IF of YAP1, and β-catenin showed an increase of YAP1 and β-catenin
localization to the nucleus in SW480+MUC13 when compare to SW480+Vector cells.
Next the PLA showed that YAP1/β-catenin was forming a complex, and that this
complex was localization in SW480+MUC13 cells. In SW480+Vector cells, this
complex stayed exclusively in the cytoplasm.
When MUC13 expression was at a loss, this interaction still happened in
SW620+shMUC13 cells, and the interaction remained in the cytoplasm. In SW620+shV,
the interaction of YAP1 and β-catenin was mostly located in the nucleus. How MUC13
influences the formation and location of this complex is not known; however, observed
roles of M|UC 13 indicates MUC13 may have a significant role in allowing cells to
develop Anoikis resistance in Colorectal cancer.
As shown in a previous study, MUC13 physically interacted with βeta-Catenin in
liver cancer upregulating the pathway [66]. With prior studies already showing an
interaction between MUC13 and β-catenin, we focused on the possible interaction
between MUC13 and YAP1. IP with YAP1 in both SW620 and HT29 showed a pull
down of MUC13. The interaction is weak indicating that the interaction does not happen
frequently in normal basal conditions but, is increased during anchorage independence in
an attempt to increase survival and confer Anoikis resistance. PLA examination at 36hr
showed us two things:
1. A nuclear interaction between both β-catenin and MUC13, and MUC13 and
YAP1.
2. A previously unreported role played by MUC13 in helping to stabilize and
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translocate YAP1 and beta-catenin to the nucleus.
We have shown, for the first time, an interaction between MUC13 and YAP1
during anchorage independence. In addition, MUC13 has also been shown to interact
with β-catenin as well. We have shown that MUC13 is a key factor in influence the
development of Anoikis resistance. Additionally, prior studies have shown that MUC13
physically interacts with β-catenin in liver cancer, upregulating its effects and oncogenic
factors [41, 66]. Is YAP1 vital to this understanding the development of Anoikis or is
MUC13/β-catenin relationship the driver of this interaction?
To answer this question, we knock downed YAP1 in SW480+MUC13 cells. We
found that loss of YAP1 expression led to a decrease in the number of cells that migrated
and invaded. This decrease in these phenotypic aspects of SW480+MUC13 displays
indicates that YAP1 expression is vital in the complex for the promotion of metastasis
and survival in CRC.
Interestingly when we knockdown YAP1 expression, we saw an increase in the
mRNA levels of MUC13, and protein levels with increase at the 55, and 30kDA bands.
At the 120kDA band, most often associated with the oncogenic potential of MUC13,
showed a decrease in this expression. This, along with the decrease in phenotypic
activity, demonstrates that YAP1 is a vital part of the complex.
Increased MUC13 expression increased tumorgenicity in-vitro in the tail vein
mouse model. SW480+MUC13 showed increased MET formation in the lung tissue,
along with increase migration to other organs within the body. SW480+MUC13 injected
cells successfully arrested in the lungs and metastasized in the kidneys. Tissues in
MUC13 mice were found to have increased YAP1, β-catenin, and MUC13 expressions,
indicating that these factors played a role in tumorgenicity and anchorage independent
survival in CRC.
In MUC13 overexpressing tissues, the kidneys showed nuclear localization of not
only YAP1 and β-catenin, but MUC13 as well. This nuclear localization present in the
kidneys, but not in the lungs, (where the primary tumor formed) indicates the importance
of the cooperation of MUC13 with YAP1 and β-catenin in anchorage independent
survival and tumorgenicity in colorectal cancer.
The validation of this relationship in mice indicated a need to examine this
relationship in human tissue as well. In the tissues studied there was not clear increase of
expression of MUC13 and YAP1 from Stage I to Stage IV. However, in Stage II and III,
where the tumor has the potential to form metastatic sites and anchorage independent
survival is the most important, YAP1 and MUC13 show their highest scoring intensity.
Specifically, in stage II, MUC13 and YAP1 showed an average score of 182 and
222 respectfully. This strengthens the argument that MUC13 and YAP1 cooperation is
need for the cell migration and survive the Anoikis process. The idea of a needed
cooperation is further strengthening when examined the average score of the 4 patients in
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which MUC13 was localized in the nucleus, which showed the higher YAP1 expression
compared to non-nuclear MUC13 samples.
This further indicates that MUC13 is helping to facilitate and increase YAP1
expression in CRC leading to increase tumorgenicity. These trends might not be
significant, as the sample size used in our study was small. Studies, with larger sample
sizes, will be needed to strengthen the trend we have identified here. Regardless of
sample size, our study shows a novel relationship involving interactions of YAP1
expression with MUC13 in CRC.
We were able to show that MUC13 confers Anoikis resistance through the
upregulation of the YAP1/Beta-Catenin survival complex in colorectal cancer. In
addition, we were able to show that MUC13 upregulates this complex by directly
interacting with β-catenin and YAP1 and helping with translocation of this complex with
direct interactions between β-catenin, YAP1 and MUC13.
In this chapter, we proposed that Anoikis resistance is achieved in colorectal
cancer through an overexpression of MUC13 that modulates Beta-Catenin and YAP1
activity in the nucleus. We have shown that MUC13 expression has a direct correlation to
Anoikis resistance when interacting with β-catenin and YAP1. Further study, however, is
needed to determine how this mechanism involving MUC13 assists β-catenin and YAP1
across the nuclear membrane. and how once in the nucleus MUC13 helps increase the
activation of β-catenin/YAP1 survival complex in CRC. This study is the first to show
MUC13 as a key player in the development of Anoikis resistance in colorectal cancer.
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CHAPTER 4.

SPLICE VARIANTS IN MUC13

Introduction
Genetic variation is a well-known aspect of most common complex diseases.
Variations, at the genetic level, are believed to account for our susceptibility to common
diseases, such as cancer. Thus, further understanding and identifying genetic variants that
occur has been main concern not just in cancer research, but in research on other diseases
as well [67]. Cancer consists of a multifactorial process. At a basic level, cancer is the
cumulation of the acquisition of multiple genomic variants through the progression of
disease. Genomic instability often entails somatic mutations and deletions within the gene
[68]. A large percentage of Colorectal cancer cases are attributed to sporadic causes.
Examining the role of genetic variations occurring in somatic cells and their relationship
to the development of Colorectal cancer is essential.
Mucins, whose main role is protection of cells in some of the harshest
environment in the body, are susceptible to genomic instability. Mucins, as a whole,
present a large group distinct gene. These mucins present polymorphic genetic variation
in their length.
In the current literature, the mucin MUC1, showed two distinct populations of a
small MUC1 allele and small MUC1 genotypes in gastric cancer. The small MUC1 allele
and genotypes exhibited a higher frequency in patients with gastric carcinoma, resulting
in a increased risk for gastric cancer carcinoma [69]. In a separate study variation in
MUC1 and MUC5AC were found to contribute to elevated risk in stomach cancer. In
MUC1 carriers with haplotype ACTAA rare alleles rs4971052, rs4276913, rs491088, and
rs4072037 had a near double risk of developing cancers as compared to the haplotype
GTAAG [70]. The presence of these mutations in membrane bound mucins and their
effect on gastric cancer indicate a similar situation might occur in the mucins involved in
CRC. MUC13 similarly to MUC1 whose, adherent expression, has been found to be a
poor prognostic marker in multiple cancers raises the question if it has and genetic
variants and their effect in cancer.
Online Bioinformatic resources have identified 5 transcripts, 82 orthologues, and
2 paralogues of MUC13(Ensemble genome browsers). Of the 5 identified splice variants
in MUC13, 2 retain their introns (MUC13-201,203) and 1 becomes a process transcript
(MUC13-204). These three transcripts do not generate any protein. The remain two
transcripts MUC13-205, and MUC13-202 translate to a protein of different lengths.
MUC13-205, which we referred to as MUC13-LF (512aa), is the main transcript which
has been investigated in literature and has shown to be oncogenic in nature. MUC13-202,
which we referred as MUC13-SF (184aa,) has not had its expression and function
investigated before.
At the mRNA level, both MUC13-LF and MUC13-SF share similarities. MUC13LF contains 12 exons, 11 which are coding; this results in a transcript length of 2,879bp.
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MUC13-SF contains 6 coding exons; which results in a transcript length of 587bp. The
difference in length of mRNA sequences and contents, allowed us to identify a
differential primer set that we could copy determine to number of the gene variants
within cancer. In this chapter we propose to characterize and validate the MUC13
isoforms responsible for is oncogenic characteristics in CRC.

Methods and Materials
Cell Culture
Cancer cell lines Mia-Paca 2 (ATCC# CRl-1420) and Panc-1(ATCC#CRL-1469) were
grown in complete DMEM media without Sodium pyruvate (Gibco Cat# 11965092) with
10%FBS ad 1% antibiotic/antimycotic. All cells were grown at 37°C supplied with 5%
CO2.

RNA Isolation, cDNA Generation
Total RNA was extracted from cells using the Trizol (Invitrogen Cat#15596018).
Integrity and concentration of isolated RNA was checked using Nanodrop 2000. 2µg of
RNA samples was reversed transcribed using Iscript gDNA clear kit (Bio-Rad
cat#1725034).

PCR
The mRNA variants MUC13 LF and MUC13 SF were identified by amplification
using Platinum™ SuperFi™ DNA Polymerase (thermosphere Cat#12351010), and
primer sequences MUC13 SF_LF (F5 ACT CTT CTT GCT CTC CTT TCT
G3’/R5’CCA GGG AAT ACC TTT CCT TTC T3’).Samples were run on a 1% agarose
gel at 100V with 100bp DNA ladder(Thermofisher Cat#15628019) and visualized using
iBright Cl1500 (Invitrogen cat# A44240).

ddPCR
The copy number of MUC13 LF and SF were determined during QX200™
ddPCR™ EvaGreen Supermix (Bio-Rad Cat# 1864033). Samples were generated into
droplets using QX200 droplet generator (Bio-Rad Cat# 1864002) that contained 20ng of
target cDNA per well, Eva Green ddPCR master mix, the Primer MUC13 SF_LF (F5’
TGG CCT ATC TGC TGC ATA GT3’/R5’AAA CTT GTC ATC AGC ACG CAT3’) or
MUC13 LF (F5’ CAG ACA GTG AGT CAA CCA CAA A3’/R5’GGA CCT GTG CTG
TTT AGG GT3’), and Eva Green droplet oil. Samples were than run though a
thermocycler and read by QX200 Droplet reader (Bio-Rad Cat# 1864003). Data was then
analysis using QuantaSoft™ Analysis Pro Software QuantaSoft-Analysis-Pro-v1.
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Immunofluorescence
Cells were seeded at a density of 4x104 per chamber in a 4-well chamber slide
and then transfected. Cells were then washed with PBS and fixed for 30mins using
4%PFA (cat# J61899-AP). 4% PFA was removed with PBS and cells were then
permeabilized with 2% Triton X-100 for 5 mins, block in 10% Donkey serum for 1 hr.
Slides were then incubated overnight primary antibodies (anti-Flag mAb (Sigma Aldrich
Cat# F3165) and anti-MUC13 C18 (in house) in 5% Donkey serum. After washing,
samples were incubated in Cy3 anti-rabbit and Alexa 488 anti-mouse respectively at
room temperature in 5% donkey serum for 1 hr. Finally, slides were mounted with Vector
Shield with DAPI (VECTASHIELD Cat#H-2000) and images were captured at 40x oil
magnification using a confocal microscope Images were captured using a confocal
microscope (Zesis 710 UTHSC core) and analyzed using Zesis version blue.

Plasmid Generation and Transfection
MUC13 long form and its vector were acquired from abmgood (Cat# LV230821).
The Short form MUC13 was cloned in abmgood Vector pLenti-GIII-EF1α with a 3xFlag
tag at the (NheI and BamHI). Plasmids were isolated using Promega Midi kit as per
manufacturer manual (Promega Cat# A7640) followed by further purification by Phenol
Chloroform method. Plasmids were transfected into Mia-Paca-2 and Panc-1 cells using
Lipofectamine Ltx (Invitrogen Cat # 15338030) following manufactures
recommendations.

Cell Migration Assay
Panc1 Vector, MUC13 LF, and MUC13 SF3xFlag were starved in FBS- media
overnight before being seed at a density of 10,000 cells in FBS-media in the upper
chamber of a HTS Transwell-96 well permeable with 8µm polyester membrane (Corning
Cat# 3374) with FBS+ media being added to the bottom well. After 48hr incubation cells
were fixed with 4%PFA (Cat# J61899-AP) and stained with crystal violet.

Cell Invasion Assay
To ascertain the effect of knocking down MUC13 SF in Mia-Paca-2 and Pan-1,
cells were starved the night before invasion assay in FBS- media. Cells were then seeded
at a density of 20,000 cells in the upper chamber of 8.0-micron Corning Matrigel
Invasion Chamber (Corning Cat# 354480), with FBS-media in the bottom chamber of a
24-well plate. After approximately 12hrs media in the lower chamber was replaced with
FBS containing media. Plate was then incubated for 24hrs and cells were fixed with cold
methanol and stained with crystal violet.
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Research Involving Human Tissue
Human Pancreatic tumor RNA samples were procured from the Department of
Pathology, University of Tennessee Health Science Center (UTHSC, Memphis, TN,
USA) as per UTHSC IRB guidelines. Archived FFPE tissues were used in this study. The
tissue samples were coded to de-identify any patient information. Therefore, it is
considered that “no human subjects” were involved in this study. The study was
conducted in accordance with the Declaration of Helsinki, and the “Human Subject
Exempt protocol” was approved by the Ethics Committee of the UTHSC, Memphis, TN,
USA; project identification code 13-02690-XM, approved on 28 August 2013.

Statistical Analysis
GraphPad Prism 7 (GraphPad Software, GraphPad La Jolla, California, USA) was
used for statistical analyses of all experimental procedures. Assays comprising with two
groups with equal or unequal variance, unpaired two-tailed Student’s t-tests or t-test with
Welch’s correction was performed, respectively. In instances with 3 or more groups, twoway ANOVA statistical tests were performed followed by Sidak’s multiple comparison
test for pairwise analysis. In all cases, a p-value of <0.05 was considered statistically
significant.

Results

MUC13 Splice Variants Structural Similarities and Differences
MUC13 is a mucin located on chromosome 3 from 124,905,442-124,953,819 on
the reverse strand. Online bioinformatics sources were able to identify 5 different splice
variants of MUC13. Three of these splice variants MUC13-204,203, and 201 however,
did translate to a protein variant. The remaining two splice variants MUC13-202(SF) and
MUC13-205(LF) are protein coding variants. MUC13-204 is considered a processed
transcript upstream of all the transcripts overlapping on the chromosome with the first
part of MUC13-202, and 205. MUC13-204 Contains 5 exons, of which none are coding
exons. The MUC13-203 and 201 splice variants retain introns and are non-protein
coding. MUC13-201 overlaps on the chromosome with back half of MUC13-LF, while
MUC13-203 overlaps with MUC13-SF and MUC13-LF.
MUC13-LF consist of 12 exons, 11 of which are coding resulting in a sequence
length of 2879bps. Of those 11 exons, MUC13-LF shares 6 with MUC13-SF, with a
sequence length of 587bps. However, through sequence alignment, it was determined that
MUC13-SF is missing the last few base pairs of Exon 1 and a significant portion of exon
2. MUC13-SF only contained the last 69bps of the 462bps in Exon 2. The last difference
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in sequence of the shared exons between MUC13-SF and MUC13-LF is exon 6. MUC13SF exon 6 only contains the first 145 bps of the total 164bps. The difference in the
number exons and total bps results in two different length proteins. MUC13-LF is
predicted at 512aa compared to the 184aa predicted length of MUC13-SF.
MUC13-LF consist of a single peptide region, a Tandem repeat domain, a EGFlike domain 1, SEA domain, EGF-like domain 2 and 3, a Transmembrane domain, and a
Cytoplasmic tail. These features are typically of a membrane bound mucin, with a cleave
domain within the SEA domain of MUC13. MUC13-SF, however, consists of only the
single peptide except aa 17-20(TATN), aa 148-171 of the tandem repeat domains, shares
the EGF-like domain 1, and aa 212-315 excluding the last 20 aa of the domains. MUC13SF does not contain 2 or 3rd EGF-like domain, the TM domain, or the cytoplasmic tail
(Figure 4-1).
IF imaging of MUC13-SF, in which we tagged it with a 3xFlag tagged, showed a
successful transfection and translation of MUC13-SF in Mia-Paca cells. MUC13-SF was
found to be localized in the cytoplasm. When we probed with C18, a MUC13 anti-body
produced in-house raised against MUC13-LF, the IF-imaging showed no signaling on the
MUC13-SF transfected Mia-Paca cells (Figure 4-2).

Copy Number Variation in Cancer Cell Lines of MUC13-LF and MUC-SF
The distinct differences between MUC13-LF and MUC13-SF allow for us to
study the differential expression of mRNA copy number between the two protein coding
transcripts, MUC13-LF and MUC13-SF. As seen Figure 4-1 were MUC13-SF and
MUC13-LF shared part of Exon 1 we were able to design two sets of primers. One set of
primers MUC13-SF_LF amplifies both transcript variants with the area of amplification
being shared between the SF and LF. The second set of primers MUC13-LF, share a
common area on the reverse primer, but the forward primer lands only MUC13-LF
specific mRNA sequences translated by the sequences of Exon1 and Exon2 that was not
shared with MUC13-SF. ddPCR further allowed us to extract the SF population of
MUC13 out of the total MUC13 population by taking the difference between the
MUC13-SF_LF amplification and MUC13-LF amplification. The difference of the two
amplification gave us the MUC13-SF population.
This method allowed us to see the mRNA copy numbers of both MUC13-LF and
MUC13-SF in eleven different cancer cell lines between Colorectal cancer and Pancreatic
cancer. The cell lines SW480, HCT116, and BxPC3 showed little expression of both
MUC13-LF or MUC13-SF. Among those with scarce MUC13 copy number expression
MUC13-LF was the dominant variant expressed.
This trend was observed even among cell lines with much greater copy numbers
of MUC13. T84, LoVo, HPAFII, and ASPC1 showed the greatest amount of MUC13
mRNA levels. Each one excluding ASPC1 had a small population of the MUC13-SF
splice variant.
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Figure 4-1. Identification of MUC13 splice variants
(A). Five identified splice variants of MUC13, at their genomic coordinates highlighting
their exons, and status. (B). mRNA sequence alignment between MUC13-LF(1-1000bp)
and MUC13-SF(1-552bp) using a global alignment (Needleman-Wunsch). (C) Domain
breakdown of MUC13-LF and MUC13-SF highlighting the specific aspect of each splice
variant.
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Figure 4-2. MUC13-SF localized to the cytoplasm of Mia-Paca-2 cells
(A). Immunofluorescence of Flag and MUC13(C18) of Mia-Paca-2 MUC13-SF. Panels
read from left to right DAPI, target, and merged image.
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The two Pancreatic cell lines Panc1 and Mia Paca-2 had been previously shown to be
MUC13 null in previous studies performed in our lab. Panc1 and Mia Paca-2 in our
results validated what was previously found in having no MUC13 mRNA expression
(Figure 4-3).

MUC13-SF Expression Leads to a Decrease in Oncogenic Potential
In examining the effects of MUC13-SF on the oncogenic potential of cancer, we
first investigated the copy number levels during Anoikis between the isogenic cell lines
SW480 and SW620. MUC13-SF expression showed basal level expression at 0hr in both
SW620(52coplies/µL), and SW480 on the agarose gel. In SW620 MUC13-SF expression
was lost at 24hrs, along with a decrease in the overall expression going from 800 to 414
copies/µL. SW480 showed an increase in total MUC13 levels from 25 to 56 copies/µL at
24hrs. MUC13-SF demonstrated a minor expression with 3 copies/µL. MUC13-LF
expression in SW620 increased from 36 to 48hrs, while MUC13-SF expression returned
at 36hrs only to decrease again at 48hrs. In SW480 MUC13-LF copy numbers said
similar with MUC13-SF following a similar pattern as SW620. The trend of MUC13-SF
however in SW480 was not as drastic SW620 (Figure 4-4).
Null MUC13 expression cell lines Mia Paca-2 and Pan-1 were transfected with
plasmids generating MUC13-LF and MUC13-SF_3xflag to determine the effect of
MUC13-SF expression on their phenotypes. Cell invasion assay showed a significant
decrease in the number of cells invaded in MUC13-SF expressing cells compared to the
Vector in both Panc-1 and Mia-Paca-2. In cells expressing MUC13-LF we saw a
significant increase in the number of cells invaded nearly double that of Vector cells
(Figure 4-5). Investigating the effect of MUC13-SF further, we observed how MUC13SF affected the ability of cells to migrate. MUC13-SF expressing Panc1 cells showed a
significant decrease in the number of cells migrating compared to that of the Vector cells.
MUC13-LF expressing cells had nearly double the number of cells that migrated
compared to those of the Vector (Figure 4-6).

Discussion
Genetic variation is often a major aspect of complex disease development. Cancer
is a disease in which affects caused by genetic mutations are the main driver in its
development. Mucins, which are found in the some of the harshest environments within
the body, are particularly vulnerable to the formation of genetic variants. In Gastric
cancer, genetic variations in MUC1 and MUC5AC have been found to lead to poor
pathological outcomes and increased risk of disease development [69, 70]. In this study
we examined 5 splice variants in MUC13, identified by ensemble genome browser, and
their effects to the oncogenic phenotype associated with its adherent expression.
Three of the splice variants were found to be non-protein coding, and therefore
not significant for our study. We concluded that most likely that these variants, two
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Figure 4-3. mRNA copy number of MUC13-LF and MUC13-SF
(A). Quantification of mRNA copy number of MUC13-LF and MUC13-SF in cancer cell
lines, with average number of MUC13-LF and MUC13-SF copies presented over each
cell line.
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Figure 4-4. Loss of MUC13-SF mRNA copy number during anchorage
independent stimulation
A). PCR of MUC13-LF and MUC13-SF of SW480 and SW620 across the anchorage
independent stimulation of 0,24,36, and 48hrs. (B) Quantification of mRNA copy
numbers of MUC13-LF and MUC-SF across 0,24,36, and 48hrs of anchorage
independent stimulation. Average copy number is reported above each cell line.
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Figure 4-5. MUC13-SF reduces invasion in Mia-Paca and Panc-1 cells
(A). Images of Matrigel invasion of Panc1 and Mia-Paca+Vector, MUC13-LF, and
MUC13-SF (left to right). (B) Quantification of number of cells that migrated of Panc1
and Mia-Paca+Vector, MUC13-LF, and MUC13-SF (left to right) and quantification of
the number of cells invaded. Data are represented as mean ± SEM. Unpaired t-test
followed with Welch’s correction*p < 0.05, **p < 0.01, ***p < 0.001 and ****p <
0.0001 denote significant differences.
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Figure 4-6. MUC13-SF reduces migration in Panc1 cells
(A). Images of cell migration assay of Panc-1 Vector, MUC13-LF, and MUC13-SF (left
to right). (B) Quantification of the number of cells migrated. Data are represented as
mean ± SEM. Unpaired t-test followed with Welch’s correction*p < 0.05, **p < 0.01,
***p < 0.001 and ****p < 0.0001 denote significant differences.
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whom retain introns, and one a process transcript, most likely are translational debris.
These variants are most likely the result of early termination in the transcriptional
process, or mishaps in the transcriptional process.
The remaining two spice variants; MUC13-205, which we refer to as MUC13-LF
in this paper; and MUC13-202, referred to as MUC13-SF, are protein coding. They share
a similar mRNA sequence sharing. MUC13-SF shares 6 exons with the longer MUC13LF, which in contains an additional 6 exons, 5 of which are coding. MUC13-SF contains
a significant portion of Exon 1, but not all of it. MUC13-SF also was missing a large
portion of Exon 2. The missing sequence and exons resulted in a significantly different
protein composition when compared to MUC13-LF.
While MUC13-SF shares the EGF-like domain with MUC13-LF, it did not
contain the whole single peptide, it was missing the large section of the TR domain, and
the last 20aa of the SEA domain. MUC13-SF was completely lacking the EGF-like
domains 2 and 3, TM domain, and cytoplasm tail. MUC13-SF lack of TM domain
indicates MUC13-SF is either contained in the cytoplasm or secreted. The IF of MUC13SF showed a localization only in the cytoplasm. MUC13-SF, lacking the above domains,
and with localization only showing in the cytoplasm, point to MUC13-SF being
contained in the cytoplasm. However, we did not look for secreted proteins MUC13-SF
could still be secreted like mucins MUC2 and MUC5AC. Whether MUC13- SF acts as a
gel-forming, or non-gel forming, mucin is not clear. Further research is needed to
determine that attribute.
MUC13-SF, sharing most of it sequence with MUC13-LF, would be hard to
determine which population of MUC13, MUC13-SF or MUC13-LF, you are seeing when
preforming OT-PCR or ddPCR studies. MUC13-SF does not share a large portion of
Exon 2 which allowed for us to generate a set of differential primers. One set of primers
amplifies both splice variants, while the other set of primers only amplifies MUC13-LF.
A ddPCR examination, with these differential primer sets, enables us to examine if there
are any copy number variations in Colorectal cancer and pancreatic cancer. MUC13-LF
showed significantly higher ratios of expression compared to MUC13-SF than that of
MUC13-SF. In the SW480 we saw a small number of copies of MUC13-LF and MUC13SF, however in SW620, its metastatic counterpart, we saw a large number of copies of
MUC13-LF and no MUC13-SF. The cell lines HT29, T84, LoVo, HPAFII and ASPC1
showed overall lager number of MUC13 mRNA copies with most of those copies being
LF or only LF, depending on the cell. MUC13-SF was not the predominant variant
presence in any of the cell lines. We did not examine the presence of MUC13-SF or
MUC13-LF in normal Colorectal or Pancreatic cell lines, but the lack of SF expression
suggests evidence of MUC13-SF behaving as an anti-tumor phenotype.
After cloning the MUC13-SF variant in MUC13 null cells Panc1 and Mia-Paca,
we were able to investigate the effect of MUC13-SF on the oncogenic phenotype
associated with MUC13. In both migration and invasion assays, we saw a significant
decrease in the number of cells that migrated or invaded. This was a stark contrast to
cells, in which MUC13-LF was overexpressed, as they showed nearly double the number
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of cells invading or migrating. The decrease in migration and invasion, as observed with
MUC 13-SF, points to it acting as a tumor suppressor. This along with the lack of mRNA
levels in cancer cells suggests that loss of MUC13-SF is involved in the prevention of
cancer progression or protection of the cell. This is more evident in Anoikis where
MUC13-SF expression rises at 36hrs before becoming nonexistent. These reactions by
MUC13-SF could be the host cells response to protect itself from Anoikis or attempts to
lessen the ability of MUC13 to promote Anoikis resistance. In SW480 cells, MUC13-SF
expression increase just like SW620, but the ratio of SF to LF is much higher, in SW480
cells, and this might result in the increased death we see in the cell line compared to
SW620. While this evidence suggest that MUC13-SF expression leads to tumor
suppression the expression of SF and LF in these phenotypic assays was artificially
created. The next step will be isolating this variant at the mRNA and protein level.
Isolation will allow for a more complete study and give insight into to life of MUC13
from normal epithelial to cancer.
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CHAPTER 5.

CONCLUSION

The ability of cancer cells to survive in circulation, and then invade into distant
sites, is a key aspect of metastasis. While less than 0.02% of these cells entering the
blood stream and survive, the damage they do is lethal, therefore, understanding the
mechanism enabling these cells survive is vital [12]. MUC13 has been shown to be
involved in increased cell growth, migration, invasion, and colony formation of cancer
cells [38, 39, 43, 66, 71]. With indirect activation of anti-apoptotic pathways, such as
PI3K/AKT, MUC13 has also been shown to protect colorectal cancer cells from
apoptosis [39]. Because MUC13 appears to enable cancer cells to survive apoptosis,
examining the role of MUC13 in anchorage independent survival is of great interest. Our
study, for the first time, shows that MUC13 plays an important role in anchorage
independent survival of CRC cells through interaction, stabilization, and nuclear
translocation of YAP1 and β-catenin, thereby inducing expression of their downstream
target oncogenes.
An anchorage independent in vitro survival model (Anoikis model) was
established in the lab to mimic the environment of tumor cells in circulation. This,
Anoikis model, allowed us to investigate molecular mechanisms that are operating during
this condition. Two isogenic CRC cell lines, (SW480; originated from primary tumor and
SW620; originated from metastatic lesion), were chosen for this investigation. In our
Anoikis model, SW480 cells exhibited 60% cell death at 36hrs while, SW620 cells
exhibited only 20% cell death under the same conditions. This suggests that SW620 an
inherent ability to develop anchorage independent survival (Anoikis resistance)
Interestingly, SW620 cells demonstrated higher MUC13 expression level, compared to
SW480 cells, when we determined comparative MUC13 expression level between these
isogenic cells. This provides some indication that cells with greater MUC13 expression
are more impervious to loss of contact with the ECM pathway and that MUC13 might
play a role in the survival of the cells. Thus, to mechanistically define the role of MUC13
in Anoikis resistance, we generated MUC13 overexpressing cell lines and MUC13
knockdown stable cell lines. MUC13 overexpression in SW480 cells drastically
improved survival of these cells in Anoikis model, while MUC13 knockdown in SW620
cells reduced their survival. In addition to survival in Anoikis model, MUC13 expression
influenced spheroid formation capabilities of SW480 and SW620 cells, and number of
live cells in the spheroids, after being introduced to anchorage independent survival for
36 hrs. These phenotypes were correlated with the sustained expression of MUC13 and
Bcl2 and caspase cleavage during survival of cells under the anchorage independent
conditions. This data confirms the vital role of MUC13 in cancer cell survival during
Anoikis.
To further understand how MUC13 protects cells from cell death during
anchorage independent environment, or in circulation, we performed a Kinome assay on
high (SW620) and low (SW480) MUC13 expressing cells. This assay suggested
differential expression of several kinases in these cells. Among several, most apparent
differential alterations in SW480 and SW620 at 36 hours were observed in pAKT, pFAK.
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This confirms that the Anoikis induction model we developed is properly inducing
Anoikis and Anoikis resistance in high MUC13 expressing (SW620). The differential
expression in pGSK3-α/β, and total β-catenin indicated an increase in the Wnt/β-catenin
signaling pathway, and a possible association between MUC13/β-catenin during Anoikis
resistance. Additionally, when we altered MUC13 expression (overexpressed or
knockdown), the expression of key downstream genes of Wnt/ β-catenin (Axin2, C-Myc,
and Cyclin-D1) was influenced in SW480 and SW620 cells. This data suggest influence
of MUC13 on nuclear translocation of β-catenin. The expression of these three genes
have also been shown to be upregulated by MUC13 in liver cancer [66]. The increased
expression of Axin2 indicated an increased stabilization and translocation of β-catenin,
and increased expression of c-Myc oncogene [72].
Studies have also shown interaction and complex formation of two key molecules
(β-catenin and YAP1) Wnt/β-catenin and Hippo-YAP1 pathways during colorectal
tumorigenesis [8, 60-62, 73, 74]. In our study, noting the interaction between βcatenin/YAP1, we sought to determine if MUC13 is involved in the nuclear translocation
of β-catenin/YAP1. First, looking at YAP1 expression, it was found that MUC13
expression was directly correlated with the expression of YAP1 protein. Additionally,
ectopic MUC13 expression enhanced the nuclear localization of YAP1 and β-catenin in
SW480 cells. This effect was apparent in SW480 cells as these cells have sizable basal
nuclear β-catenin expressions [62]. Further we examine if loss of MUC13 had an effect
of this co-localization in the nucleus.
In SW620 at 36hrs the loss of MUC13 resulted in the loss of co-localization in the
nucleus. Considering these findings, we speculated that if MUC13 physically interacts
and forms a molecular complex with YAP1 and β-catenin, then this allows Colorectal
cancer cells to develop Anoikis resistance. Of note, in the co-localization
immunofluorescence, there was an increase in YAP1 and β-Catenin localization in the
nucleus. At this time, however, it is not known how MUC13 expression was related to
this increase in co-localization. As shown in a previous study, MUC13 physically
interacted with βeta-Catenin in liver cancer upregulating the pathway [66]. However, this
study did not indicate if MUC13 was facilitating the translocation of β-catenin to the
nucleus.
In the study next examined MUC13 formed a molecular interaction between the
complex of YAP1/β-catenin was a possibility by using IP to pull down MUC13 with
YAP1 in normal conditions. The IP showed a weak interaction between MUC13 and
YAP1. This weak interaction may have been due interaction between MUC13 and YAP1
only happening in significant numbers during time in which the cells were going through
anchorage independent growth.
We next examined the molecular interaction with MUC13 through a Proximity
Ligation Assay (PLA), which confirmed MUC13 complex formation with both β-catenin
and YAP1. PLA became the preferred technology in this study because, very limited
numbers of cells survived in Anoikis model after 36 hours, and secondly it can provide
information regarding the subcellular localization of the interaction.
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Conventional, immunoprecipitation (IP) technique was not suitable for this study
of the mechanism during Anoikis. Our PLA results are in accordance with a previous
study that has shown MUC13 interaction with βeta-Catenin in liver cancer (Dai et al.,
2018). PLA study defined three main points:
1. Increased interaction of YAP1 and β-catenin in the nucleus at 36hrs in
MUC13 overexpressing cells.
2. Pronounced interaction and molecular complex formation of MUC13 with βcatenin and YAP1,
3. MUC13 facilitates stabilization and nuclear translocation of YAP1 and βcatenin. This molecular interaction induced the expression of their
downstream target oncogenes to provide Anoikis resistance in cancer cells
during the anchorage independent survival period.
The results showed that MUC13 was vital to the localization of YAP1/MUC13/βcatenin complex that increased survival and oncogenic potential. We were unclear if
YAP1 was vital to this process or if MUC13/β-catenin was the main driver. We then
proceed to knockdown YAP1 expression in SW480+MUC13 cells, which resulted in an
increase of MUC13 at the mRNA and protein level. MUC13, at the protein level, showed
greater intensity at the 55, and 30kDA bands. At the 120kDA band, believed to be the
indicator of the oncogenic potential of MUC13, MUC13 was less when YAP1 was in
knockdown. Loss of YAP1, resulted in a decreased in the number of cells that invaded
and migrated compared to normal SW480+MUC13 cells. These finding allowed us to
conclude that YAP1 was vital along, with MUC13, for the survival and progression of
Colorectal cancer.
For cells escaping from Anoikis; their extravasation, homing and colonization are
necessary next steps for successful metastasis to occur at distant organ sites [12]. With
respect to Fidler’s findings, we investigated if MUC13 would also provide Anoikis
resistance to cancer cells, thus facilitating the next steps of metastasis. Our in vivo
metastasis studies in the tail vein mouse model showed that the ectopic MUC13
expression provided metastatic advantage to the SW480-MUC13 cells as evident, from
the presence of visible metastatic lesions in kidneys, lungs, and liver. No micro or macrometastatic lesions, however, were observed SW480-vector control cells. High expression
of MUC13, YAP1 and β-catenin was observed in metastatic lesions present in lungs and
kidney. The nuclear expression of YAP1, MUC13 and β-catenin was also evident in the
metastatic lesions, however, it was more prominent in the kidney lesions compared to
lesions in lungs. This may explain why kidneys showed more pronounced metastasis
states, when compared to lungs and liver states of metastasis. This data clearly suggests
that MUC13 is critical player in facilitating nuclear translocation of YAP1, and β-catenin,
cooperating with these oncogenic proteins elevating their metastatic functions in cancer
cells. Clinical significance of this novel molecular interaction was evaluated in different
stages of colorectal cancer samples. Higher expression of MUC13 and YAP1 was
observed at different tumor stage serial cut samples and compared to adjacent normal
appearing samples. Interestingly, tumor samples that showed nuclear MUC13 expression,
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demonstrated higher YAP1 expression. This strengthens the argument that MUC13 and
YAP1/ YAP1/β-catenin cooperation is need for the cells to move out from the primary
tumor, survive Anoikis, and promote metastasis at distant organ site.
Expression of Genomic variants of genes within cancer often leads to a change in
the phenotype of the cell. Whether the change is oncogenic, or tumor suppressive, differs
on a case-by-case basis. In MUC13, through bioinformatic search, we discovered that
MUC13 has 5 known genomic variants. Three of these variants are non-coding, while the
last two code for proteins. We designated the longer variant of 512 amino acids as the
long form, and the shorter of with 184 amino acids the short form. Examining Pancreatic
and Colorectal cancer cell lines, we found a differential expression of these two variants,
with the long form being the dominant variant. We then examined if the short form
expressed a different phenotype, as compared to the long form. Using the MUC13 null
cell line Panc-1, and Mia Paca-2, we transfected both the short form and long forms, to
see if there was an observed phenotypic change in the cells. Short form expression leads
to a decrease in the cells that invaded and migrated when compared to the vector. These
results allowed us to deduce that short form expression resulted in a less aggressive
phenotype.
We further saw this when examining the expression of the variants during
Anoikis. We found that as SW620 cells progressed through the time points short form
expression gradually decreased at times long form was the only variant expressed.
When examining the localization of short MUC13 in cells after transfection, IF showed a
localization of the Short form to the cytoplasm. MUC13-SF was not detected with we
used the in lab generated MUC13 anti-body C18. C18 was raised against MUC13-LF and
the inability of C18 to detect the short form revels a structural difference between the
long form and short form MUC 13 in cells. We found that the Short form MUC 13 cells
share most of same cell domains, up to the SEA domain, of the long form. The Short
form MUC 13 cells do not encompass the TM, and cytoplasmic tail domains.
We suspect that short form MUC 13 cells behave as a protective agent, once
secreted, prevents the cell and oncogenic signaling of the MUC13 by blocking its
receptor sites. Loss of short form MUC 13 cells, as it is secreted, results in activation of
MUC13 related oncogenic pathways. Further study of these genomic variants is further
needed to properly identify the functions of short form MUC 13. Our study revealed that
the expression of the short form variant, of MUC13 in cells decreased the oncogenic
potential of cancer cells.
While MUC13 is most likely not the only player in the development of Anoikis
resistance, it clearly plays an important part in the development of Anoikis resistance. In
the proteomic study, we found that SOX2 expression was increased in SW620 cells at
36hrs compared to SW480 cells. With plasticity of the cells being an important part in
Anoikis resistance development we originally explored SOX2 expression in Anoikis
stimulation.
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In examining the expression of SOX2 in correlation with MUC13 expression, we
found that in MUC13 overexpression leads to loss of SOX2 at protein and mRNA levels
in SW480 cells during Anoikis. The loss of MUC13 expressional SW620 cells, resulted
in increased SOX2 expression at protein and mRNA levels. These results provide
evidence to SOX2 involvement in the promotion of MUC13 expression during Anoikis.
This is further supported by SOX2, role as a transcription factor and downstream
activator of β-catenin. With MUC13 expression peak occurring at 36 hours it is possible
that once SOX2 is upregulated by β-catenin early in Anoikis the cells need MUC13
expression to survive (Figure 5-1). We were able to identify five possible binding sites
for SOX2 in MUC13 promoters. The identified binding sites along with MUC13
expression increasing or decreasing depending on SOX2 expression indicates SOX2
promotes the expression of MUC13 (Figure 5-2).
Whether or not SOX2 expression in anchorage independent stimulation leads to
MUC13 expression and development of Anoikis resistance has yet to be determined. The
results, however, provide a clear path for further investigation, in which we can further
understand the role of MUC13 in Colorectal cancer and its progression through
metastasis.
This study was the first step in the identification of the novel interaction of
YAP1/MUC13. The results call for a further need to investigate this interaction. In the
future we propose to further investigate this novel interaction between MUC13 and
YAP1 by identifying and characterizing their interaction domains. To further examine the
oncogenic pathways the complex MUC13/YAP1/β-catenin is responsible for
upregulating. To investigate regulation of SOX2 purposed above and how this relates to
the progression of Anoikis resistance in CRC.
In conclusion; using an Anoikis model (in vivo metastatic model) and CRC
patients’ samples; we have identified a novel molecular mechanism that provides Anoikis
resistance to detached tumor cells during circulation and facilitates metastasis of these
cells at distant organ sites. Our study reveals that MUC13 play critical roles in these
metastases associated processes via interaction and complexation with YAP1/β-catenin
and their translocation to the nucleus (Figure 5-3). In addition, we found the short form
genomic variant of MUC13 created a decreased oncogenic potential in Panc1 and Mia
Paca-2 cells. Therefore, we propose that blockage of complex formation between
MUC13 and YAP1/β-catenin represents a novel molecular target to develop newer
therapeutics for the treatment of metastatic cancer. The restoration of short form MUC13
could be a method of promise in developing new therapeutics for more efficient and
effective treatments of metastasis associated with CRC.
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Figure 5-1. Interplay between MUC13 and SOX2 during anchorage independent
stimulation
(A). Western Blot representing SOX2 expression during of SW480+Vector and
SW480+MUC13 during 0,24,36, and 48hrs of anchorage independence. (B) mRNA
expression levels of SOX2 during Anoikis in SW480+Vector and SW480+MUC13 cells.
(C) Western blot analysis of SOX2 expression during 0,24,36, and 48hrs anchorage
independence in SW620+shVector and SW620+shMUC13. (D) RTPCR for mRNA
expression of SOX2 at different times during Anoikis assay for SW620+shV and
SW620+shMUC13 respectively. Data are represented as mean ± SEM. Two-way
ANOVA followed by Sidak’s multiple comparison test. *p < 0.05, **p < 0.01, ***p <
0.001 and ****p < 0.0001 denote significant differences.
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Figure 5-2. SOX2 regulates MUC13 expression
(A). Western blot and QT-PCR representing MUC13 expression in stable Sox2
overexpressing cells. (B) Western blot and QT-PCR representing MUC13 expression in
stable knockdown Sox2 cells. (C). MUC13 genomic region; 1330bp containing Exon 1
and 1200bp upstream. Highlighted regions are potential Sox2 binding sites within
MUC13 promoter region. Data are represented as mean ± SEM. Unpaired t-test followed
with Welch’s correction*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 denote
significant differences.

90

Figure 5-3. Schematic representation of MUC13/YAP1 mechanism of action
during Anoikis.
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